Graduate Theses, Dissertations, and Problem Reports
2002

Expression and regulation of c-myb in B-lymphocyte development
Candice LaShawn Damiani
West Virginia University

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Damiani, Candice LaShawn, "Expression and regulation of c-myb in B-lymphocyte development" (2002).
Graduate Theses, Dissertations, and Problem Reports. 1699.
https://researchrepository.wvu.edu/etd/1699

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

EXPRESSION AND REGULATION OF C-MYB IN B-LYMPHOCYTE
DEVELOPMENT

Candice LaShawn Damiani

Dissertation Submitted to the School of Medicine at West Virginia University
in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
In
Microbiology, Immunology, and Cell Biology

Kenneth S. Landreth, Ph.D., Chair
John B. Barnett, Ph.D.
Laura F. Gibson, Ph.D.
David Weissman, M.D.
Eric H. Westin, M.D.

Department of Microbiology, Immunology, and Cell Biology
Morgantown, West Virginia
2002

Keywords: Myb, Bone Marrow, Lymphopoiesis, Hematopoiesis, Pro-B Cell, Stromal
Cell
Copyright 2002

ABSTRACT
EXPRESSION AND REGULATION OF C-MYB IN B-LYMPHOCYTE DEVELOPMENT
Candice L. Damiani
B lymphocytes are continually produced in bone marrow from pluripotential
hematopoietic stem cells. Lymphopoiesis is characterized by a series of highly
regulated genotypic and phenotypic changes resulting in immunocompetent effector
cells which express cell surface immunoglobulin. Our laboratory has focused on
defining extracellular signals regulating lymphoid progenitor cell survival, proliferation,
and differentiation. These studies have demonstrated that pro-B cell survival,
proliferation, and differentiation are regulated by interactions with fibroblastic stromal
cells in the hematopoietic microenvironment. However, specific molecular mechanisms
by which stromal cells regulate B lymphoid development are largely unknown. In an
attempt to better understand molecular mechanisms regulating maturation in this
lineage, we developed a panel of pro-B cell clones from 14-day murine fetal liver.
These pro-B cell clones remain dependent on stromal cells for survival, do not form
tumors, and reconstitute B lymphocytes in severe combined immunodeficient (SCID)
mice. In vitro, pro-B cell clones continuously proliferate and do not differentiate. We
noted that pro B cell lines were characterized by expression of high levels of the
oncogene c-myb. Although several laboratories have proposed a role for c-myb in
regulation of hematopoiesis, virtually nothing is known about the function of c-myb in
normal B lineage cells. To investigate the role of c-myb in the survival, proliferation, and
differentiation of B lineage cells, we utilized a stromal cell dependent pro-B cell line that
expresses mRNA and protein for c-myb. Experiments utilizing RT-PCR and Western
blot analysis reveal that c-myb is regulated in pro-B cells by stromal cells, specifically by
stromal cell adhesion contacts. Both DMSO and antisense oligonucleotides were used
to downregulate c-myb protein to determine the role this intracellular regulator plays in B
lymphocyte development. Our investigations revealed that downregulation of c-myb did
not affect pro-B cell survival but did interrupt both pro-B cell proliferation and
differentiation. In vivo investigations in mice carrying homozygous mutations of the cmyb gene indicate that lymphopoiesis is severely diminished in embryonic knockout
animals. These data suggest a central role for c-myb in proliferation and differentiation
of developing B lymphocytes.
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CHAPTER 1

REVIEW OF LITERATURE
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I. INTRODUCTION
Hematopoiesis is the continual development of red and white blood cells from
pluripotential hematopoietic stem cells. The hematopoietic system is a dynamic system
consisting of hematopoietic stem cells (HSC) that are retained in blood forming tissues
throughout life. HSCs have the ability to both self-renew as well as constantly give rise
to the different types of mature blood cells, including cells of the erythroid, myeloid, and
lymphoid lineages (Kincade, 1989).

During embryonic development, hematopoietic

stem cells migrate from the aorta/gonad/mesonephros (AGM) region through a series of
tissue sites. In the fetal liver, hematopoietic stem cells mature and differentiate to form
committed lymphoid and myeloid progenitor cells. Progenitor cells are distinguished
from HSC’s by progressive loss of self-renewal capacity and restriction of
developmental options. Lymphoid and myeloid progenitors subsequently differentiate
through a series of committed developmental stages to form effector cells. Effector
cells leave hematopoietic tissues, have a finite lifespan, and are continuously
repopulated from committed progenitor cell populations in hematopoietic tissues.
Bone marrow is established as the primary site of hematopoiesis shortly before
birth and this remains the primary hematopoietic organ throughout postnatal life. Bone
marrow is characterized by packed hematopoietic cells interspersed with a meshwork of
non-hematopoietic cells termed stromal cells. Fibroblastic stromal cells within the bone
marrow are required for normal hematopoiesis.

Stromal cells support early cell

development through cell adhesion interactions that bind receptors on developing
hematopoietic cells. In addition, stromal cells secrete hematopoietic cytokines into the
marrow environment, including interleukin-7 and c-kit ligand (stem cell factor), which
stimulate lymphocyte development (Billips, 1992). These secreted stromal cell products
are necessary for continued hematopoiesis (Dorshkind, 1990).
In addition to cellular events, it has become evident that molecular mechanisms
are also involved in controlling gene expression, proliferation and differentiation in the
hematopoietic system. Different developmental fates of individual cells must be strictly
controlled to keep the immune system balanced. On the molecular level, the
hematopoietic system is useful for studying how decisions are made to differentiate
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along one of several alternative pathways and how characteristic patterns of lineage
specific gene expression are generated. The importance of underlying regulatory
mechanisms is underscored by the fact disruption of these controls can lead to various
diseases, such as leukemia.
The Myb family of proteins is a group of transcription factors that bind DNA and
were first identified as part of avian myeloblastosis virus. The oncogene responsible for
the transformation in avian leukemia is v-myb. V-myb protein is a constitutively active,
mutated, and truncated form of C-myb, a product of the c-myb proto-oncogene. The cmyb proto-oncogene encodes a 75 kDa nuclear protein that binds to a consensus
sequence of DNA [(T/C)AAC (T/G)G ] (Bidenknapp, 1988). C-myb expression is high in
immature hematopoietic cells, and levels of c-myb decrease as immature cells
differentiate to function (Lipsick, 1996). C-myb is also over expressed in many forms of
leukemia.

In 1982, Westin et al investigated c-myb expression in a human

promyelocytic leukemic cell line and determined that overexpression of c-myb inhibited
differentiation of the cell line (Westin 1982). These data were the first to suggest that cmyb dysregulation inhibited normal progression through lineage development and that
appropriate expression of c-myb was required for normal myelopoiesis. Based on this,
a critical role for c-myb in myelopoiesis was proposed. C-myb must be expressed in
immature myeloid cells in order for proliferation to occur, but must then be downregulated for terminal differentiation of myeloid cells. Since c-myb is expressed in all
immature hematopoietic cells, it was hypothesized that c-myb may play a pivotal role in
the development of other blood cell types as well. Gewirtz demonstrated that inhibition
of c-myb expression using anti-sense oligonucleotides resulted in growth arrest of
hematopoietic cells (Gewirtz, 1988).

The development of a mouse model with a

homozygous mutant c-myb gene confirmed these data.

Animals with homozygous

interruption of c-myb transcription were normal at day 13 of gestation, but by day 15
were severely anemic and expired in utero. These animals exhibited a complete loss of
myelo and erythropoiesis in the fetal liver (Mucenski, 1991). These in vivo observations
further suggested that c-myb is normally required for the maintenance of myelopoiesis
as well as erythropoiesis. The role of c-myb in lymphopoiesis, however, has been more
poorly defined.
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Survival, proliferation, and differentiation of B lymphocytes depend on a set of
regulatory signals from the hematopoietic microenvironment provided in bone marrow.
Expansion of pro-B cells is dependent on the cytokine interleukin-7 (IL-7) in conjunction
with a series of co-stimulatory cytokines including insulin-like growth factor-1 (IGF-1)
(Gibson, 1993). Stem cell factor, or c-kit ligand, is expressed by stromal cells and binds
to the tyrosine kinase receptor c-kit expressed on hematopoietic cells. Murine models
deficient in c-kit or c-kit ligand result in failure of fetal liver hematopoiesis (Nagasawa,
1996). Expression of both the anti-apoptotic gene bcl-2 and the pro-apoptotic gene bax
in pro-B cells is also regulated by stromal cells (Gibson, 1996).
In this study, we addressed the role of c-myb in B lymphopoiesis. The aims of
this project were to explore normal expression patterns of c-myb in developing B
lymphocytes, to determine whether the hematopoietic microenvironment regulated
expression of c-myb in these cells, to determine the effect of c-myb down regulation on
lymphocyte differentiation, and to determine if loss of myb impacts B lymphopoiesis in
the fetal liver.
II. HEMATOPOIESIS
Developmental hematopoiesis.

Hematopoiesis describes the continual

development of red and white blood cells from a small population of pluripotential
hematopoietic stem cells. Murine experimental systems have been extensively utilized
to study the process of hematopoiesis. Insight into embryonic murine hematopoiesis
has proven to be extremely informative since it has been determined that murine and
human fetal hematopoiesis display many parallels. (Ghia et al, 1998). Embryogenesis
extends over a 21-day period in the murine system. During this time hematopoiesis is
initiated, sequentially progresses through other fetal organ systems, and eventually
resides in the bone marrow as depicted in Figure 1.
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Figure 1. Sequential Progression of Murine Hematopoiesis During Ontogeny
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Hematopoiesis initiates extraembryonically in hemangioblasts, or blood islands of
the yolk sac, at approximately day 7 of murine gestation (Metcalf and Moore, 1970).
Within the mouse embryo, the paraaortic splanchnopleura (P-Sp) is endowed with
hematopoietic potential (Godin, 1993 and Medvinsky, 1993). The P-Sp comprises the
dorsal

aorta

and

surrounding

mesoderm.

This

region

develops

into

the

aorta/gonad/mesonephros (AGM) region, which continues to possess hematopoietic
potential (Cumano et al, 2001; Moore et al, 1970).

It is proposed that multipotent

progenitors may arise simultaneously in the P-Sp/AGM region and in the yolk sac. On
day 10 of gestation, hematopoietic cells from the AGM region and/or the yolk sac travel
through the blood stream into the fetal liver. In mammals, the fetal liver is the principal
site of hematopoiesis during mid and late gestation. Multipotent progenitors in the fetal
liver express the cell surface markers AA4.1 and Sca-1, and lack expression of lineage
specific markers (Jordan, 1995). Fetal liver hematopoiesis can be divided into four
stages: the onset of hematopoiesis (day 10), the expansion of hematopoiesis (day 1112), the peak of hematopoiesis (day 13-14), and the involution of hematopoiesis (after
day 15) (Sasaki, 2000).

By day 15, the spleen begins to function as a subsidiary

hematopoietic organ until just after birth (Cumano et al, 2001a; Morrison, 1995). The
bone marrow becomes a hematopoietically active site on day 17 as cells from the fetal
liver traverse into the marrow environment. The bone marrow functions as the primary
site of hematopoiesis after birth (Cumano et al, 2001a).
Hematopoietic stem cells.

The first suggestion that stem cells were

responsible for hematopoiesis was in the late 1890s by Ehrlich (Ehrlich, 1879; Ehrlich,
1898). Ehrlich first conceptualized an ancestral stem cell that was capable of dividing to
maintain a constant population while also producing progeny that could mature into
various cells of the blood system. From a smear of triacid-stained bone marrow, he
noticed one particular cell type he described as a “primitive large basophilic
mononuclear cell with a vesicular nucleus and few or no granules”. He termed this cell
the Myelozyt, or marrow cell, and suggested that it was the precursor of granulocytes
but not lymphocytes.

This dualistic theory of development was challenged by

Pappenheim who, in 1899, used an improved staining method to detect a “relatively
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featureless primitive” cell that he coined the Lymphoidozt (Pappenheim, 1989;
Pappenheim, 1900). Pappenheim suggested a monophyletic concept of development;
he proposed that the lymphoidozyt was actually the source of all blood cell development
(Wintrobe, 1980).
Hematopoietic stem cells were further studied in response to a clinical quandary.
Patients with cancer needed to receive high doses of chemotherapy to eradicate
cancerous cells; however, this treatment often resulted in lethality. A radio-protective
cell was needed to overcome this lethality. The radio-protective cell would be able to
rapidly reconstitute hematopoietic activity sufficient to rescue a lethally irradiated
recipient from hematopoietic failure. The task, however, was locating this cell. This
question was first addressed in 1949 when Jacobsen et al showed that lead shielding of
hematopoietic tissues during lethal irradiation prevented death (Jacobson, 1949). This
suggested that radio-protective cells resided somewhere within hematopoietic tissues.
Then, in 1951, Lorenz showed that infusion of syngenic marrow after irradiation also
protected patients from death (Lorenz, 1951). Together, these data suggested that
radio-protective cells were located in hematopoietic tissues, specifically in the bone
marrow. Till and McCulloch further expanded this hypothesis in 1961. They discovered
that the bone marrow contained progenitor cells capable of giving rise to myeloid,
erythroid, and megakaryocytic cell colonies in the spleens of irradiated hosts (Till and
McCulloch, 1961). Hematopoietic cells were injected into lethally irradiated mice and,
after ten days of recovery, hematopoietic nodules had formed on the surface of the
spleen. Morphologic examination of the spleen revealed the nodules were composed of
immature erythroid and myeloid cells. Based on these observations, Siminovitc (1963)
proposed that within the bone marrow there existed a cell population capable of multilineage differentiation, self-renewal, and radioprotection (Siminovitc, 1963).

Prior to

Siminovitc’s theory, Osgood, in 1957, had proposed that there existed a population of
cells that underwent asymmetric divisions, forming a daughter cell that would mature
into a specialized blood cell while also forming a replacement stem cell during the same
division (Osgood, 1957). These cells described by Osgood and Siminovitc were termed
hematopoietic stem cells.

Following the discovery of Till and McCulloch, Wu et al

(1967) tracked stem cell development (using induced chromosomal aberrations) and
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determined that each nodule that developed on the spleen of a reconstituted irradiated
host was a clone of cells derived from a single precursor cell. However, neither group
had identified Siminovitc’s proposed stem cell population that could reconstitute both
the myeloid and lymphoid lineage. Then, in 1977, Abramson et al finally identified a
pluripotential stem cell that could mature into both myeloid and lymphoid lineage cells.
Again, they used chromosomal aberrations to track the progeny of stem cells. Their
model suggested the existence of a pluripotential stem cell compartment, with multilineage reconstitution capabilities, as well as restricted stem cell compartments,
committed to development in a single lineage (Abramson, 1977).
Pluripotential hematopoietic stem cells are the most primitive cells involved in
blood cell development.

These stem cells originate in the P-Sp of the developing

embryo and then migrate to the fetal liver (Godin et al, 1999). Beginning on day 17 of
gestation, hematopoietic stem cells seed the bone marrow microenvironment and
produce all hematopoietic cell populations in postnatal animals. It is estimated that
hematopoietic stem cells represent up to 0.05% of cells within the bone marrow
(Spangrude et al, 1988).
Hematopoietic progenitor cells. Progenitor cells are distinguished from HSCs
by being a lineage-committed population that has lost the capacity to self-renew.
Lineage-committed progenitor cells are progeny from stem cells that have begun to
differentiate into mature cells but are at very early stages of cell development. It was
hypothesized that the commitment to differentiate in the myeloid or lymphoid lineage
was irreversible once commitment had occurred. This was confirmed in 1997 when
Kondo et al identified a clonogenic common lymphoid progenitor from murine bone
marrow. This Lin- IL-7R+ Thy-1- Sca-1lo C-kitlo population exhibited lymphoid-restricted
reconstitution capacity while lacking myeloid differentiation potential (Kondo, 1997).
Three years later, Akashi et al isolated an IL-7Rα- Lin- C-kit+ Sca-1- FcγRlo CD34+ cell
population that demonstrated myeloid lineage restriction with no lymphoid potential
(Akashi, 2000). The authors suggested that the common lymphoid progenitor (CLP)
and the common myeloid progenitor (CMP) represented the earliest branch point
between the lymphoid and myeloid lineages. The CLP and the CMP then undergo
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differentiation events themselves, become more mature committed cells, and eventually
develop into end cells. The CLP differentiates into both T and B cells of the immune
system.

Myeloid end cells include erythrocytes, platelets, monocytes, neutrophils,

eosinophils, and basophils.
Recent literature from Lu et al has called the accepted dogma of hematopoietic
progression into question (Lu et al, 2002). Work from their laboratory indicates that no
CLP exists in the fetal liver.

Rather, they suggest that a common myelolymphoid

progenitor (CMLP) and a common myeloerythroid progenitor (CMEP) are the first
branch points from the hematopoietic stem cell. Their system detected progenitor cells
with myeloid/erythroid/lymphoid potential (thought to be the HSC), myeloid potential,
myeloid/erythroid potential, myeloid/lymphoid potential, myeloid/T cell potential, and
myeloid/B cell potential. However, no cells with only lymphoid (T and B cell) potential
were detected. These data are reminiscent of data presented in 1977 by Abramson
where no CLP could be detected. This disputes the developmental scheme proposed
by Weissman and colleagues described above (Kondo, 1997 and Akashi, 2000).
Therefore, although this dissertation presents an overall view of the currently accepted
dogma in hematopoietic development, new data are constantly emerging which
challenge current thinking.
III. MYELOID CELL DEVELOPMENT
Regulation of hematopoietic events has been extensively studied in the myeloid
lineage.

Myeloid progenitor cells differentiate into at least 6 morphologically and

functionally recognizable cell types.

Developing myeloid progenitor cells have

characteristics of a myeloblast, promyelocyte, and finally differentiated end cells.
Differentiation of myeloid progenitors into more mature myeloid cells is characterized by
an anti-proliferative state in which cells withdraw from the cell cycle into the G0 phase
(Boyd 1984). This cell cycle withdrawal is accompanied by down-regulation of the cmyc oncogene (Westin, 1982), rapid induction of the c-fos oncogene (Barzilay, 1987),
and decreased expression of histone genes (Brelvi, 1987).

Concurrently, the cell

acquires a morphologically differentiated phenotype. Differentiated myeloid cells have
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condensed nuclei, loss of nucleoli, and altered cell surface receptors.

Myeloid

differentiation has primarily been studied using tumor cell models comprised of cells
blocked in a specific hematopoietic differentiation state.

Use of tumor cell models

allows the study of specific stages of hematopoiesis since tumor cells are “frozen” in a
particular developmental stage. The HL-60 cell line is an in vitro model system of
myeloid cell differentiation that is particularly useful. HL-60 cells are a human leukemic
cell line established from the peripheral blood leukocytes of a patient with acute
promyelocytic leukemia.

HL-60 cells are primarily promyelocytes arrested in an

immature proliferative state, but they can be induced to terminally differentiate by a
variety of agents including DMSO and butyric acid (Collins, 1977).
IV. REGULATION OF MYELOID CELL DEVELOPMENT BY C-MYB
.

The Myb family of proteins is a group of transcription factors that bind DNA. This

family was first identified in the avian myeloblastosis virus. The oncogene responsible
for the transformation seen in the avian leukemia is v-myb. The V-myb protein was
found to be a constitutively active, mutated, and truncated form of C-myb, a product of
the c-myb gene.

The c-myb gene is highly conserved throughout evolution. C-myb

has been identified in all types of eukaryotes, including vertebrates, fungi, insects, and
plants (Ness, 1996). The c-myb proto-oncogene encodes a 75 kDa nuclear protein,
comprised of 636 amino acids, that is expressed in most hematopoietic tissues (Gonda,
1983 and Westin, 1982). In addition, an 89 kDa c-myb protein has been identified that
is an alternatively spliced mRNA product. The 89 kDa protein has 363 base pairs
inserted between exons 9 and 10, termed region 9A, for a total of 999 amino acids
(Rosson et al, 1987). C-myb exhibits a sequence-specific DNA binding activity, binding
in vitro to the consensus sequence [(T/C)AAC (T/G)G], where the first A, third C, and
fifth G are involved in very specific interactions (Bidenkapp, 1988 and Tanikawa, 1993).
C-myb appears to function as a regulator of transcription by mediating interactions
between specific DNA sequences and other protein components of the transcription
machinery. The modular structure of the C-myb protein is similar to that of many other
transcription factors.

C-myb proteins have a DNA binding domain at the amino
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terminus, a centrally-located transactivation domain, and a negative regulatory domain
at the carboxy terminus (Ness, 1996).
C-myb DNA binding domain. The hallmark of the Myb family of proteins is their
unique DNA binding domain. The first one-third of the protein consists of three tandem,
50 amino acid direct repeats termed R1, R2, and R3. The three repeats resemble a
homeodomain composed of three connected alpha helices. Within the tandem repeats,
there is a periodic occurrence of tryptophans that form a hydrophobic core that
maintains the alpha helix motif (Saikumar, 1990). Each repeat has three tryptophans
that are separated by 18 or 19 amino acid residues (Anton 1988). The regularly spaced
tryptophan repeat is functionally and structurally unique in the Myb family of proteins.
Mutation of tryptophan residues significantly decreases Myb’s sequence specific DNA
binding activity (Kanei-Ishii, 1990).
Deletion analysis has shown that R2 and R3 are absolutely required for DNA
binding, but R1 is dispensable.

R1 may be involved in stabilizing the interaction

between R2R3 and target DNA (Tanikawa, 1993). Alternatively, it is hypothesized that
R1 may recognize specific flanking regions adjacent to the core binding site and
increase the DNA binding affinity of Myb (Dini, 1993). The R2R3 region of the Myb
binding domain binds both to DNA and cellular proteins. The R2R3 region is very highly
conserved between members of the Myb family, as well as between very divergent
species. The third helix of R2 and R3 is a recognition helix. These helices lie in the
major groove of the DNA and make site-specific contacts important for sequence
recognition. The third helix of R2 is in contact with the third helix of R3 enabling R2 and
R3 to cooperatively bind specific DNA sequences (Kanei-Ishii, 1995).
C-myb transactivation domain.

The transactivation domain of C-myb is

downstream of the DNA binding domain, roughly located in the middle of the protein,
and encompasses a stretch of 85 amino acids. This stretch of amino acids contains a
cluster of acidic residues and a cluster of leucine residues termed the heptad leucine
repeat region (HLR).

This area is poorly conserved throughout the Myb family, and

little is known about this region of C-myb (Sakura, 1989). Recent mutational analyses
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in yeast by Wang and Lipsick have revealed new information regarding this domain.
80% of the residues within the transactivation domain can be substituted by other amino
acids without loss of transactivation function. However, there are non-mutable residues
located in the acidic and the HLR regions.

Alanine substitutions of pairs of acidic

residues within the HLR reduced the transcriptional activation of this domain in yeast
and animal cells.

Although substitution of the acidic residues resulted in reduced

activity, substitution of leucines within the HLR did not affect transcriptional activation
ability. In addition, a single threonine (259) located between the acidic region and the
HLR would not tolerate substitution. Mutation of threonine259 resulted in decreased
domain function. Although these studies reveal the importance of the acidic residues
within the transactivation domain, the functional importance of many individual residues
within the domain remain unknown (Wang and Lipsick, 2002).
C-myb negative regulatory domain.

The C-myb negative regulatory domain

contains a putative leucine zipper motif with one isoleucine and three leucine residues
(Bedenkapp, 1988). Deletion of this c-terminal region results in an increase in the
transactivational activity of the protein, as well as an increase in the DNA binding
activity of the mutated protein (Sakura, 1989 and Ramsay, 1991).

Many cellular

proteins have been shown to bind the leucine zipper of C-myb and exhibit negative
regulation (Kanei-Ishii, 1992 and Favier, 1994). In addition, the C-myb binding domain
can interact specifically with the C-myb leucine zipper and form a Myb dimer. Once the
C-myb dimer has formed, it cannot bind to DNA.

These data indicate that

intramolecular interactions between the two ends of C-myb can serve to negatively
regulate Myb activation (Nomura, 1993). In addition to the leucine zipper, it has been
shown that two subdomains of the negative regulatory domain (NRD1 and NRD2) can
also regulate C-myb.

NRD1 is upstream of the leucine zipper while NRD2 is

downstream of the leucine zipper. Deletion of either NRD1 or NRD2 increases the DNA
binding capacity of Myb (Kanei-Ishii, 1995).

Other experiments have shown that

truncating the N-terminal domain of C-myb also results in increased DNA binding ability.
This implies that the N-terminal domain is also participating in the negative regulation of
C-myb.

It is hypothesized that C-myb may fold back on itself and allow the two
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regulatory ends to interact (Ramsay, 1995). This phenomenon would explain how the
deletion of either end of the C-myb protein leads to activation. The regulation of C-myb
DNA binding activity is complex, requiring multiple subdomains in the C-terminal
negative regulatory domain as well as a region in the N-terminal domain.
The proteins encoded by the Myb genes can be divided into two classes: those
involved in the general housekeeping function of mature hematopoietic cells and those
having growth, survival, or differentiation activities. The Myb family of proteins is unique
due to their ability to regulate the growth and differentiation of many cell types. Myb
proteins are linked with critical cell fate decisions including proliferation, differentiation,
cell cycle control, and gene expression. C-myb regulates many genes and promoters,
including CD34, mim-1, cdc-2, c-myc, IGF-1, CD4, GATA-1, IL-3Rα, and c-myb (Melotti,
1994; Ness, 1989; Ku, 1993; Evans, 1990; Reiss, 1991; Siu, 1992; Aurigemma, 1992;
Miyajima, 1995; and Nicolaides, 1991). C-myb is primarily expressed in immature
hematopoietic cells, but it is also expressed in primary fibroblasts (Sczylik, 1993),
endothelial cells (Brown, 1992), and Sertoli cells (Page, 1995). Overexpression of cmyb has also been detected in breast cancer and colon carcinomas (Guerin, 1990 and
Greco, 1994). Although c-myb is primarily found in hematopoietic cells, the majority of
the genes c-myb regulates are markers of maturity and differentiation. With this pattern
of expression and regulation it is possible that c-myb induces differentiation rather than
blocking it by activating differentiation specific genes.
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C-myb is primarily expressed in primitive hematopoietic cell tissues, the most
immature hematopoietic cells, and hematopoietic tumor cell lines.

When early

hematopoietic cells are stimulated to differentiate, there is a significant decline in c-myb
expression associated with cellular maturation. This was first demonstrated by Westin
et al in 1982. These investigators established that expression of c-myb was correlated
with specific stages of myeloid differentiation (Westin, 1982).

In 1988, Clark et al

investigated myb expression in a murine erythroleukemia cell line and demonstrated
that constitutive expression of exogenously introduced c-myb inhibited erythroid
differentiation (Clark, 1998). Although all these data implicate c-myb as a regulator of
hematopoiesis, they did not definitively establish that c-myb regulated hematopoietic
cell proliferation and/or differentiation.
Gewirtz and Calabretta confirmed the importance of c-myb in hematopoiesis
using an in vitro system.

In their experiments, they depleted normal human bone

marrow cells of adherent macrophages and T lymphocytes. They exposed the bone
marrow mononuclear cells to c-myb antisense oligonucleotides and analyzed colony
formation.

Exposure to c-myb antisense oligonucleotides resulted in a decrease in

myeloid, erythroid, and megakaryocytic colony formation. In addition to a decrease in
colony number, there was also a marked decrease in colony size indicating that c-myb
expression is also relevant to understanding the proliferation of progenitor cells. These
experiments demonstrated that c-myb played a critical role in regulating normal
hematopoiesis in vitro (Gewirtz and Calabretta, 1988, Gewirtz, 1991). These results
clearly established that loss of c-myb inhibited myeloid cell development, but they did
not examine what effect over-expression of c-myb would have on myeloid cell
development. Clarke had shown that c-myb over expression would inhibit the terminal
differentiation of erythroid cells. McClinton and collaborators further expanded upon
Clarke’s earlier findings. They investigated the effects of ectopic over expression of cmyb at different times during the induction process using a Friend virus-infected MEL
cell line. The MEL cell line is an early erythroid precursor model system that can be
induced to differentiate into mature erythroid cells using chemical inducers, including
erythropoietin and DMSO. When MEL cells are induced to differentiate, c-myb mRNA is
biphasically downregulated during early and late stages of differentiation. C-myb mRNA
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is significantly down-regulated during the early differentiation stage that occurs within
hours after chemical treatment.

C-myb rebounds to basal levels after 24 hours,

corresponding with the beginning of the middle stage of MEL cell differentiation.

In

subsequent days, during the late stage of differentiation, c-myb is down-regulated until it
reaches a maximum low when terminal differentiation occurs (Kirsch, 1986 and
Ramsay, 1986). McClinton introduced an inducible metallothionein promoter driven cmyb gene into MEL cells and expressed c-myb during different phases of differentiation.
Expression of c-myb during the early phase of differentiation did not have an affect on
MEL cell maturation, indicating that early down-regulation of c-myb is not necessary for
differentiation.

However, if c-myb was continuously expressed during the entire

induction phase, differentiation was completely blocked indicating that late downregulation of c-myb is critical for terminal differentiation of MEL cells (McClinton, 1990).
Recently, in 2001, Chen and Bender demonstrated that MEL cells could be
induced to differentiate into a more mature cell by introducing an inducible dominant
interfering myb allele (MEnT). After induction of MEnT in MEL cells, transfected cells
began differentiating and ceased proliferating with no chemical induction necessary.
These experiments were used to argue that downregulation of c-myb alone in MEL cells
is sufficient to induce terminal differentiation (Chen and Bender, 2001). Taken together
these data suggested a critical role for c-myb in myeloid and erythroid hematopoiesis:
down regulation of c-myb is required for terminal differentiation of myeloid and erythroid
cells. This pattern of expression suggests that c-myb plays a pivotal role in the
development of blood cells. The development of a mouse model with a homozygous
mutant c-myb gene confirmed these data.
Mucenski et al generated a mouse model heterozygous for a mutated c-myb
gene. A vector was constructed with a neomycin resistance gene inserted in opposite
transcriptional orientation into the sixth c-myb exon. The construct was introduced, by
electroporation, into stem cells and cells containing the construct were identified by
G418 selection.

Embryonic stem cells with the construct were implanted into

pseudopregnant female mice. The altered c-myb allele was passed to progeny animals
and the affect of the alteration was examined. Mice heterozygous for mutant c-myb
appeared phenotypically normal after birth. Animals that were homozygous null for the
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C-myb protein were normal at day 13 of gestation. They were present in appropriate
numbers and had developed brains, kidneys, lungs, hearts, and limb buds. However,
by day 15, mutant mice were pale in color, severely anemic, and expired in utero. At
days 12.5-13.5 of gestation, hematocrit levels in wild type and mutant mice were 35%.
By day 15.5, there was a 10-fold decrease in the numbers of hematocrits in the c-myb
null mice. Null mice had hematocrit levels of 5% whereas wild-type animals had 40%.
It is at this time in embryogenesis that the anatomic site of erythropoiesis moves from
the AGM region into the fetal liver.

Erythrocytes derived from the AGM can be

morphologically differentiated from fetal liver derived erythrocytes; erythrocytes from the
AGM region remain nucleated and are larger than those from the fetal liver.
Examination of peripheral blood at day 12 revealed normal numbers of nucleated
erythrocytes, indicating that early intraembryonic erythropoiesis in the AGM was normal.
However, there was a significant defect in fetal hepatic erythropoiesis.

Animals

exhibited a complete loss of erythropoiesis in the fetal liver. This indicates that c-myb
mutant mice are unable to switch the site of fetal erythropoiesis from the AGM region to
the liver (Mucenski, 1991).

These observations further suggest that c-myb is

responsible for the maintenance of myelo and erythropoiesis. Although c-myb has been
shown to be critical in the development of erythroid and myeloid precursors, less work
has been done on the role of c-myb in the normal development of lymphocytes.

V. B CELL DEVELOPMENT
The bone marrow is the primary site of postnatal B lymphocyte development in
mammals. The bone marrow microenvironment is composed of a complex meshwork of
stromal cells, developing lymphopoietic cells, and extracellular matrix. In addition, the
cells within the microenvironment release cytokines and colony-stimulating factors.
These components interact in an amazingly complex way to support the survival,
proliferation, and differentiation of B lymphocytes.

How the bone marrow

microenvironment, particularly bone marrow stromal cells, regulates the development of
B lineage cells is not completely understood. The bone marrow contains B lineage cells
at all stages of development, from the earliest progenitors to the most mature B cells. B
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lymphopoiesis in the bone marrow occurs in parallel with myelopoiesis and
erythropoiesis.

The daily production of B cells in adult mammals is very high; an

estimated 5 x 107 B lymphocytes are generated per day in mice (Landreth et al, 1981,
Rahal and Osmond, 1981).
B lymphopoiesis is characterized by the ordered progression of a stem cell
through a series of tightly controlled, systematic genotypic and phenotypic changes
resulting in formation of mature B cells. In order to survive this developmental process,
B lymphocytes must fulfill several criteria including a single productive immunoglobulin
(Ig) rearrangement at the heavy chain loci as well as a productive light chain gene
rearrangement. The initial gene rearrangements occur in the heavy chain genes. This
requires the joining of a DH (diversity) to a JH (joining) locus.

Following the DH-JH

joining, the DJH segment is juxtaposed to one of many VH (variable) regions. As the
heavy chain gene is transcribed, post transcriptional processing removes the noncoding
sequence present between the rearranged VH-DH-JH segment and the constant (C)
locus, resulting in expression of the µ heavy chain (V-D-J-Cµ). Following heavy chain
protein translation, light chain gene rearrangement occurs. This process entails joining
one of several light chain J segments to a V segment. The kappa light chain rearranges
first. If both kappa light chain rearrangements are non-productive, lambda light chain
rearrangement occurs.

If a kappa rearrangement is productive, lambda light chain

rearrangement is inhibited. Once the light chain gene is rearranged and transcribed,
the µ heavy chain associates with the light chain and the assembled Ig molecule is
expressed on the cell surface (Yancopoulos and Alt, 1986 and Oettinger et al, 1999).
As B lymphocytes undergo these genotypic alterations, the cell also acquires a number
of cell surface markers that can be used to determine discrete stages along the
developmental pathway.

Various approaches for identifying and describing cells at

different stages of B lymphoid development have been proposed based both on cell
surface phenotype and genotype.

Because of this, several different nomenclatures

have been established for the classification of B cell developmental stages. The earliest
identified cell committed to development in the B lymphocyte lineage is the common
lymphoid progenitor (CLP) that was identified by the Weissman laboratory (Kondo et al,
1997). The stages following the CLP have been described in detail by two different
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schemes based on phenotypic changes that occur during B cell development. Dennis
Osmond proposed one nomenclature scheme (Osmond, 1990).

Osmond grouped

precursor (cytoplasmic µ-) B cells into 3 classes based on expression of TdT, an
intranuclear enzyme expressed during the rearrangement of the variable region of the
heavy chain of the immunoglobulin gene, and the tyrosine phosphatase B220, an
isoform of CD45RA. Early pro-B cells are TdT+ B220-, intermediate pro-B cells are TdT+
B220+ and late pro-B cells are TdT- B220+. Pre-B cells are characterized by being
B220+ as well as cµ+. Large pre-B cells are large mitotically active cells that divided into
small non-dividing small pre-B cells.

The small pre-B cells then mature into non-

dividing, B220+, IgM+ immature B lymphocytes.

Hardy and colleagues proposed a

different scheme (Hardy et al, 1991). Hardy utilized a PCR based strategy to detect the
status of Ig gene rearrangement and then correlated gene rearrangement with
phenotype (CD43, Heat Stable Antigen (CD24), and BP-1 expression). The first genetic
event in B lineage cells is rearrangement of the D and J segments of the heavy chain
immunoglobulin gene. By Hardy’s proposed terminology, this cell is termed a progenitor
(pro-) B cell. Pro-B cells are B220lo and CD43+. In vitro, pro-B cells have long-term
proliferative capacity in the presence of stromal cells and interleukin-7 (IL-7). He further
divided the pro-B cell stage into Fraction A, Fraction B, Fraction C, and Fraction C’
based on BP-1 and heat stable antigen (HSA) expression. Fraction A cells are the most
primitive and lack expression of either HSA or BP-1. Fraction B cells express HSA but
not BP-1 while Fraction C cells express both HSA and BP-1. Fraction C’ differs from
Fraction C by expressing higher levels of HSA. Cells are classified as pre-B cells once
complete rearrangement of the heavy chain immunoglobulin gene (the V segment is
joined to the D-J segment) occurs and the heavy chain is expressed in the cytoplasm of
the developing cell. During the pre-B cell stage the heavy chain, µ, is expressed on the
surface of the cell in conjunction with a surrogate light chain. The surrogate light chain
is comprised of two molecules, V pre B and λ5. The surrogate light chain is expressed
on the surface of the pre-B cell in conjunction with Ig α and β. The pre-B cell has lost
some of its proliferative capacity and is less dependent on stromal cells and IL-7. In
addition, the pre-B cell has lost expression of CD43 on the cell surface. Then, the light
chain genes of the pre-B cell rearrange.
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After a functional rearrangement has

occurred, the heavy and light chains are expressed on the surface of the cell.
Phenotypically, cells lose expression of the IL-7 receptor but acquire cell surface
expression of immunoglobulin (IgM). This cell is now classified as an immature or virgin
B cell. Immature B cells then leave the bone marrow where a small fraction enters the
peripheral B cell pool.

After antigen stimulation, the immature B cell further

differentiates into a mature B cell expressing IgM and IgD on the cell surface.
Hardy and Hayakawa proposed a model for B cell development based on the Osmond
scheme, the early Hardy scheme, and other cell surface markers that have recently
been discovered on the surface of developing B lymphocytes.

The current model

proposes 6 developmental stages following the CLP: pre-pro-B (Fraction A), pro-B
(Fraction B/C), large pre-B (Fraction C’), small pre-B (Fraction D), new-B (Fraction E),
and mature B (Fraction F).

Pre-pro-B cells are B220+, CD43+, HSAlo, c-kitlo, Tdt+,

AA4.1+, IL-7Rα+, CD19-, and have immunoglobulin genes in germline configuration.
Pro-B cells retain the markers that pre-pro-B cells have but they also acquire CD19, Ig α
and β, surrogate light chain, Rag 1 and 2, and higher levels of HSA. These cells either
have their Ig genes in germline configuration or have rearranged the D and J loci of the
heavy chain gene.

The large pre-B cell population phenotypically resembles pro-B

cells, but they have acquired BP-1 on the cell surface. However, this cell population
has rearranged the V, D, and J loci of the heavy chain genes while the light chain genes
remain in germline configuration. The small pre-B cell acquires the expression of CD25
and µ heavy chain, while increasing existing levels of HSA. This population looses
expression of CD43, c-kit, surrogate light chain, and TdT. At this stage of development,
B lymphocytes rearrange either the kappa or lambda light chain of the immunoglobulin
gene. New B cells no longer express BP-1, IL-7Rα, CD25, Rag 1, or Rag 2. New B
cells have completely rearranged heavy and light chains and they express mu and
kappa or lambda. Mature B cells are characterized by the loss of AA4.1 as well as a
decrease in HSA expression (Hardy and Hayakawa, 2001).

Since this is the most

recent model proposed that considers all the genotypic and phenotypic changes that
occur in B lymphopoiesis, this work will refer to stages in B cell development based
upon this developmental scheme (see Figure 2).
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Figure 2. Model of B lineage development. Model depicts hematopoietic stem cell
development (HSC) through mature B cell development. Expression of cell surface
markers and progression of immunoglobulin gene rearrangement are shown. Cell
surface markers are described as follows:
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AA4.1

Cell surface antigen recognized by the AA4.1 antibody

B220

220kD from of CD45 restricted to expression in B lineage cells

CD43

Leukosyalin

HSA

Heat stable antigen

BP-1

B lineage restricted glycoprotein

c-kit

Stem cell factor receptor

IL-7Rα

α chain of the interleukin-7 (IL-7) receptor

CD19

90 kD B cell specific cell surface antigen

CD25

Interleukin-2 (IL-2) receptor α chain

Ig α/β

Anchor the pre-B cell receptor and assist in signaling

SLC

Surrogate light chain of the pre-B cell receptor

Rag 1/2

Recombinase activating genes

TdT

Terminal deoxynucleotidyl transferase; gene encoding machinery for
immunoglobulin gene rearrangement; expressed only in bone marrow

Adapted from Hardy and Hayakawa, 2001.
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The survival, proliferation, and differentiation of B lymphocytes depend on the
hematopoietic microenvironment provided in the bone marrow. This microenvironment
provides both particular cell types and cytokines that are necessary for B lymphocyte
maturation. In particular, B cells in the bone marrow develop in close association with
surrounding, non-hematopoietic, fibroblastic mesenchymal stromal cells found in the
intrasinusoidal spaces of the bone marrow, indicating that cell-to-cell contact may be
necessary for B cell development. In fact, studies of the bone marrow have revealed a
close, physical association is maintained between stromal cells and developing blood
cells (Chen and Weiss, 1975).

Experiments to delineate the interactions between

stromal cells and B lymphocytes have only been possible in recent years.

The

development of long term cultures of B lymphocytes, as well as the development of
stromal cell lines that could support lymphoid cultures in vitro, were required to allow
stromal cell/B cell interactions to be dissected (Whitlock and Whitte, 1982 and Johnson
and Dorshkind, 1986).

The observed close association between early B cells and

adherent stromal cell layers led to investigations of the adhesion interactions occurring
between the two cell types. It is now apparent that adhesion contacts are necessary for
retaining lymphopoietic cells in the marrow environment and for promoting their
continued survival. One essential adhesion molecule found on stromal cells is vascular
cell adhesion molecule-1 (VCAM-1 or CD106). VCAM-1 is a 170 kDa glycoprotein
expressed on the surface of stromal cells that belongs to the immunoglobulin supergene family. VCAM-1 is the ligand for VLA-4, a heterodimer belonging to the integrin
family, expressed on the surface of lymphopoietic and myelopoietic cells.

The

importance of this interaction was demonstrated when antibody that blocked the VLA-4
molecule expressed on lymphoid cells ablated adherence of lymphoid cells to bone
marrow stromal cells (Miyake et al, 1991 and Kina et al, 1991).
Literature had clearly indicated that stromal cells were responsible for regulating
the survival of early B cells (Johnson and Dorshkind, 1986). To more clearly describe
these interactions, Gibson and colleagues described a murine pro-B cell line, C1.92,
from day 14 fetal liver that required stromal cells and IL-7 for continued growth. They
demonstrated that the model murine pro-B cell line was completely dependent upon
stromal cells for continued survival (Gibson, 1993). When cultured in the presence of
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the cloned stromal cell line, S10, for 24 hours pro-B cells maintained high cell viability.
However, when pro-B cells were cultured in media alone for 24 hours, their viability was
reduced to 5%, indicating that pro-B cells require survival factors provided by stromal
cells. Gibson then looked at expression of the proto-oncogene bcl-2, a known antiapoptotic molecule. When pro-B cells were removed from stromal cell culture, there
was a rapid decrease in bcl-2 mRNA and a corresponding rapid increase in mRNA
levels for bax, a known pro-apoptotic molecule. These results suggested that stromal
cells control the survival of progenitor B cells by regulating pro- and anti-apoptotic
factors (Gibson, 1996).
Previous experiments had demonstrated conclusively that stromal cells were
involved in the regulation of B lineage cell survival. However, the factors necessary to
promote B cell proliferation and differentiation had still not been elucidated. It was
possible that, in addition to providing adhesion interactions and survival signals, stromal
cells may also provide proliferative and differentiative signals.

The first important

interaction to be elucidated was reported in 1988 by Namen et al who demonstrated
conclusively that B cell progenitor proliferation was stimulated by a 25 kD stromal cell
derived cytokine termed interleukin-7 (IL-7) (Namen et al, 1988). The importance of IL7 in B cell development is underscored by experiments that show blocking the IL-7R or
neutralization of IL-7 in the bone marrow results in a developmental B cell block (Sudo
et al, 1993 and Grabstein et al, 1993). This observation was confirmed in 1994 when a
targeted gene disruption of the IL-7R severely arrested B cell development in the bone
marrow of mutant mice (Peschon et al, 1994).
Other cytokines were shown to be important in 1990 when Billips et al
demonstrated that the cytokines interleukin-1 (IL-1) and interleukin-4 (IL-4) regulated
stromal cell support of pre-B cells. They showed that treating a cloned stromal cell line,
S17, with IL-4 or IL-1 completely abrogated the ability of S17 to support pro-B cell
development.

These data indicated that cytokine levels in the microenvironment

influence B cell development, and stromal cells can be the targets of local cytokine
influence (Billips et al, 1990). Billips continued to investigate the role of stromal cells in
B lymphopoiesis by determining the effect of stromal cell derived cytokines on B cell
proliferation and differentiation. IL-7 was known to be the major proliferative cytokine
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produced by stromal cells.

It was also known that stromal cells produce other

cytokines, including c-kit ligand (KL) (Huang et al, 1990). KL, also known as stem cell
factor, serves as a ligand for the tyrosine kinase receptor c-kit that is expressed on
hematopoietic cells. Murine models deficient in c-kit or KL resulted in prenatal lethality
in at days 13 to 15 of gestation due to loss of fetal liver hematopoiesis (Russell, 1979).
Experiments Billips performed indicated that KL synergized with IL-7 to provide a strong
proliferative stimulus to B220+ B-lineage cells. However neither of these cytokines,
individually nor in combination, could induce the maturation of B220- cells into B220+
cells; differentiation of progenitor B cells into pre-B cells required the presence of
stromal cells.

These data were critical in demonstrating that stromal cells provide

separate proliferative and differentiative signals to developing B lineage cells (Billips et
al, 1992).
Further experiments revealed that stromal cell derived insulin growth factor-1
(IGF-1) could also potentiate the proliferative effects of IL-7 on B lymphocytes, similar to
the synergy observed between IL-7 and KL (Landreth et al, 1992). To further delineate
specific stages of B lymphopoiesis that respond to IL-7, KL, and IGF-1, Gibson et al
used the murine pro-B cell model, C1.92, discussed previously. These pro-B cells were
dependent on stromal cells and IL-7 for continued growth. Gibson demonstrated that
IL-7 was absolutely necessary for pro-B cell expansion in culture; however the addition
of recombinant KL, IGF-1, or KL/IGF-1 significantly increased the proliferation of the
pro-B cells as evidenced by increased tritiated thymidine uptake (Gibson et al, 1993).
Flt3 ligand (FL) is another early hematopoietic growth factor expressed by
stromal cells. Like KL and IGF-1, FL stimulated little proliferative activity on its own but
could synergize with IL-7 to stimulate progenitor B cell proliferation (Ray et al, 1996).
Together, these results suggest that pro-B cell expansion is depended on at least four
stromal cell derived cytokines; IL-7 delivers the primary proliferative signal while KL,
IGF-1 and FL synergize with IL-7 to increase proliferation. Another chemokine that is
expressed constitutively by bone marrow stromal cells is stromal cell derived factor-1
(SDF-1). SDF-1 was shown to stimulate the proliferation of B cell progenitors in vitro
(Nagasawa, 1994).

Nagasawa continued to explore the function of SDF-1 in

lymphopoiesis by developing a mutant mouse model harboring a targeted disruption in
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the SDF-1 gene. The majority of mice lacking the SDF-1 gene expired in utero at day
18.5 of embryogenesis. In mutants that were born, significantly reduced numbers of
pro-B and pre-B cells were observed, indicating that SDF-1 was required for the
expansion of early B lymphocytes (Nagasawa, 1996).

Together, all of these data

emphasize the importance of stromal cell derived proliferative signals to normal
development of B lymphocytes.
Although signals that regulate B cell proliferation have been proposed, it is clear
that these same signals are not solely responsible for directing B cell maturation. On
their own, IGF-1 and FL could not stimulate pro-B cell proliferation, although they could
cooperate with IL-7 to increase proliferation. However, further insights into these two
molecules revealed that they had yet another function.

When Landreth et al

investigated stromal cell derived IGF-1, they found that treatment of bone marrow
cultures with recombinant IGF-1 resulted in cytoplasmic µ heavy chain expression while
treatment with anti-IGF-1 antibody completely ablated stromal cell stimulated pro-B cell
differentiation. IGF-1 was necessary and sufficient to stimulate B cell differentiation
(Landreth et al, 1992). Ray demonstrated that FL also had an important role in B
lineage differentiation. He reported that, in the absence of stromal cells, the growth
factor combination of Flt3 ligand, IL-7, and IL-11 was able to support B cell
differentiation from early progenitor cells (Ray et al, 1996). These data suggest that FL
and IGF-1 play a dual role in B cell development; they potentiate IL-7 induced
proliferation and promote B cell maturation.
Taken together, these data revealed that B cell development is critically
dependent on stromal cells and the bone marrow microenvironment.

Stromal cell

regulation of B cell development is extremely multifaceted, and in vitro experimental
systems may never be completely representative of the complexity of the bone marrow
microenvironment. Although many of the mechanisms through which this regulation is
exerted have been discovered, the entire scope of genes that stromal cells may
regulate, and the specific mechanisms by which stromal cells exert this regulation, are
largely unknown.
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VI. REGULATION OF LYMPHOID DEVELOPMENT BY C-MYB
As previously discussed, several investigators have proposed that c-myb plays a
pivotal role in the maturation and development of myeloid cells. However, the role of cmyb in the development of lymphoid cells is less clear. Bender et al (1987)
demonstrated that constitutive expression of c-myb was necessary to maintain pre-B
leukemic cells in culture and that down regulation of c-myb correlated with partial
differentiation of these cells as evidenced by J chain secretion and decreased levels of
N-myc and BP-1.

This indicated that, as in myeloid cell development, c-myb

downregulation was required prior to differentiation (Bender, 1987). Using both the preB cell lymphoma line that Bender used, as well as a B cell lymphoma line, Catron et al
investigated the cell cycle regulation of c-myb mRNA in murine B lymphoid tumors.
They found that c-myb expression in the pre-B cell lymphoma was constitutive, but cell
cycle regulated in the more mature B cell lymphoma line. The authors suggested that cmyb may be constitutively expressed in immature, highly proliferative cells but cell cycle
regulated in more mature, differentiated cells, therefore exerting its effects by switching
from a constitutive to a cell cycle mode of regulation as lymphoid cells mature (Catron et
al, 1992).
Most work done on the role of c-myb in lymphoid development has focused on T
lymphocytes. During T cell development, the earliest committed T cell precursor that
migrates from the bone marrow to the does not express CD4, CD8, or the T cell antigen
receptor (TCR) (triple negative cell).

The most immature double negative (DN)

thymocyte is CD44lo CD25-. These cells retain the ability to develop into T and B
lymphocytes as well as NK and dendritic cells (Guidos et al, 1989, Wu et al, 1991). This
cell then matures into the CD44+CD25- population that begins to rearrange T cell
receptor β genes (Godfrey et al, 1993). During T cell receptor gene rearrangement, the
DN cell acquires CD25 and becomes CD44+ CD25+.

After the T cell expresses a

functional T cell receptor β chain, CD25 is downregulated and CD4 and CD8 are coexpressed on the surface of the cell. The CD4+CD8+ cell is termed a double positive
(DP) thymocyte. The DP stage is the time when thymocytes undergo the repertoire
selection process (Bevan et al, 1994). T cells surviving the selection process then
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downregulate either CD4 or CD8 to become mature single positive (SP) T cells (Robey
and Fowlkes, 1994). During T cell maturation, c-myb is expressed at high levels in
immature thymocytes found in the thymic cortex (Churilla et al, 1989). As in myeloid
development, c-myb levels decrease in T cells as they mature. However, when resting
T cells in the periphery are stimulated to proliferate after antigen exposure, c-myb
becomes active again (Stern and Smith, 1986). As the activated T cells undergo G1
progression c-myb expression peaks, indicating that c-myb expression is required for
entry into S phase (Gewirtz, 1989).
Direct study of c-myb in thymocyte development has been complicated by the
embryonic lethality of the c-myb null mouse.

In order to circumvent this problem,

Badiani et al used a Myb DNA-binding domain linked to the Drosophila Engrailed
transcription repressor domain to act as a dominant interfering Myb.

This allowed

investigation of the effects of loss of c-myb expression on T cell development. When
the dominant negative myb was expressed in transgenic mice, T cell development was
severely disrupted. The thymii of myb deficient animals were very small, malformed,
and had 20 times less thymocytes than normal. Flow cytometric analysis revealed that
thymic cells in c-myb deficient mice were arrested at the DN to DP transition. This
stage in thymocyte development is characterized by rapid expansion and loss of c-myb
inhibited this process of proliferative expansion. In addition, thymocytes isolated from
these animals were compromised in their proliferative response to mitogen stimulation,
consistent with the notion that c-myb is involved in thymocyte proliferation (Badiani et al,
1994). Salomoni et al used a CTLL-2 T-cell line to further determine the function of cmyb in T cell development. When IL-2 dependent, cytotoxic T lymphocytes (CTLL-2)
were transfected with constitutively active myb or c-myb antisense, CTLL-2 cells
proliferated when exposed to low levels of IL-2 and were less susceptible to apoptosis
induced by dexamethasone or withdrawal of IL-2. Although c-myb overexpression did
not confer IL-2 independence, it did lower the threshold of IL-2 necessary for CTLL-2
cell proliferation and survival.

The resistance to apoptosis observed in cells with

overexpressed c-myb was also accompanied by an up-regulation of bcl-2 expression.
CTLL-2 cells expressing the antisense construct were not able to proliferate in low
levels of IL-2 and they underwent apoptosis more quickly after treatment with
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dexamethasone or withdrawal of IL-2 than did control cultures. These data suggest that
c-myb is involved in regulating the survival of T cells and that c-myb may protect T cells
from apoptosis by inducing bcl-2 expression (Salomoni, 1997).
RAG-1 and RAG-2 gene products are essential components of site-specific DNA
recombination events in lymphocytes (Oettinger, 1990). These molecules make up the
recombinase complex which recognizes specific nucleotide sequences flanking
rearranging gene segments, termed recombination signal sequences (RSS), and
introduce DNA breaks between these signals and DNA segments (Gellert et al, 1997).
RAG-1 and RAG-2 are expressed at high levels in the earliest T and B cell progenitors
until assembly of the T cell receptor β chain or the Ig heavy chain gene is complete
(Grawunder et al, 1995 and Wilson et al, 1994). A mutation in either the RAG-1 or
RAG-2 gene completely blocks lymphocyte development at an early progenitor stage by
preventing V-D-J recombination (Mombaerts et al, 1992 and Shinikai et al, 1992). Since
Rag1-/- mice are unable to generate mature lymphocytes due to lack of a functional
antigen receptor gene rearrangements, implanting ES cells from c-myb wild type or null
animal allowed the role of c-myb in lymphopoiesis to be directly examined (Allen et al,
1999). C-myb wild type ES cells implanted into Rag deficient animals developed into
mature lymphocytes bearing cell surface immunoglobulin.

Conversely, c-myb

-/-

embryonic stem cells implanted into Rag1-/- animals were not able to reconstitute the
spleen with mature B220+ mIgM+ B cells and less mature B220+ CD43+ cells could not
be detected in the bone marrow. This indicates that ES hematopoietic stem cells from
c-myb-/- animals cannot commit to B lineage development. It was also determined that
C-myb -/- ES cells were not capable of TCR gene rearrangements, resulting in a
developmental block at the CD44lo CD25- double negative T cell stage. These data
indicate the early developmental progression of both T and B lymphocytes is dependent
on c-myb (Allen et al, 1999).
Since both the expression of c-myb and the RAG genes are necessary for
lymphocyte development, Wang et al looked at the role of c-myb in regulating RAG
gene expression. C-myb is known to regulate a wide variety of genes, and Wang et al
identified a consensus c-myb binding site within the RAG-2 promoter region.
Investigation of this site revealed that c-myb could transactivate RAG-2 by binding to
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this region and that this transactivation was critical for RAG-2 activity in T lymphocytes
(Wang et al, 2000).

These data correlate well with observation that immature

thymocytes in the cortex express RAG-1 and RAG-2, since they are undergoing V-D-J
recombination at the TCR loci, as well as high levels of c-myb mRNA.

It was not

known, however, if c-myb regulated RAG expression in developing B cells as well as in
T cells. Kishi et al determined that c-myb does bind to the RAG-2 promoter in B cells.
But, c-myb binds cooperatively with the B lineage specific transcription factor Pax-5 to
synergistically activate the RAG-2 promoter in B cells.

In addition, their studies

revealed that there is direct protein-protein interaction between c-myb and Pax-5, and
that this interaction required the C-terminal region of c-myb. This is the first evidence
that the hematopoietic specific transcription factor c-myb can cooperate with a B lineage
specific transcription factor, such as Pax-5, to activate genes necessary for lymphoid
development (Kishi et al, 2002). These data suggest that c-myb is essential for RAG-2
activation in both B and T lymphocytes and therefore regulates the process of antigen
receptor gene rearrangements.
The majority of information presented here describes the role of c-myb in T cell
development and parallels cannot always be drawn between T and B lymphoid
maturation. B lymphocytes develop in conjunction with stromal cells in the bone marrow
microenvironment.

Because of this, the regulation of c-myb in B lymphocyte

development may differ greatly from that of T lymphocytes. Stromal cells have been
shown to regulate many other genes involved in B cell development, and they may also
be involved in the regulation of c-myb. Our work is intended to investigate the role of cmyb in B lymphoid development and to better understand the role that stromal cells may
play in regulating c-myb.
VII. MYB FAMILY MEMBERS
In addition to c-myb, there are two other members of the Myb family of proteins.
Like c-myb, both a-myb and b-myb are thought to be involved in the regulation of
cellular proliferation. A-myb and b-myb share extensive sequence homology with cmyb, but they are expressed in a number of different tissues. Some tissues, however,
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express more than one member of the myb family. A-myb and b-myb also encode for
nuclear DNA binding proteins that are 95kDa (751 amino acids) and 93kDa (704 amino
acids) respectively. All 3 members of the Myb family have a similar structure. Like Cmyb, A- and B-myb have a DNA binding domain, transactivation domain, and a
regulatory domain. A-myb has a negative regulatory domain like C-myb while B-myb
has only a regulatory domain. In addition, all Myb family members bind to the same
consensus DNA sequence, but they have distinct preferences for nucleotides flanking
the core binding site (Howe and Watson, 1991 and Golay et al, 1994). This differential
binding may explain the distinctive biological functions of the Myb family genes.
A-myb is expressed in a tissue-specific fashion. The A-myb protein is primarily
found in breast epithelial cells of pregnant mice and in male germ cells. A-myb has also
been detected in ovaries, brain, and germinal center B cells (Mettus et al, 1994, Trauth
et al, 1994). DeRocco et al showed in 1997 that mice over expressing the A-myb
protein develop hyperplasia of the spleen and lymph nodes. These mice exhibited
increased DNA synthesis and a polyclonally expanded B cell population (DeRocco et al,
1997). Development of a homozygous null mutant mouse deficient in a-myb revealed
knockout mice are smaller and grow at a decreased rate than wild type littermates. As
the mice mature, the males become sterile. Female a-myb mutant mice can carry and
deliver offspring, but they exhibit abnormal mammary function and are not able to nurse
the pups. Taken together, these data suggest that a-myb may serve as a mediator of
proliferation in certain cell types (Toscani et al, 1997).
B-myb is the least conserved member of the Myb family. Unlike a- and c-myb, bmyb does not demonstrate tissue tropism. Expression of B-myb protein has been found
ubiquitously in all tissues studied (Golay et al, 1991 and Kamano et al, 1995). B-myb is
the only member of the Myb family expressed during very early (before day 10) murine
embryogenesis (Sitzmann et al, 1996). In 1992, Arsura and colleagues used b-myb
antisense oligonucleotides to inhibit the proliferation of myeloid and lymphoid cells.
Expression of b-myb is correlated directly with the induction of cellular proliferation in B
and T lymphocytes, and over expression of b-myb results in increased numbers of cells
in S phase of the cell cycle (Golay et al, 1991 and Lam et al, 1992). Thus, alterations in
the amount of b-myb present in cells correlates with altered cellular proliferation.
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IX. SUMMARY
The current literature ascribes an important role to c-myb in hematopoiesis. Cmyb is expressed in immature hematopoietic cells and highly proliferative cells. C-myb
is necessary for the proliferation of myeloid and erythroid cells. Down regulation of cmyb is critical for the maturation of myeloid and erythroid progenitors into mature end
cells. Over expression of c-myb retains myeloid cells in a proliferative state and inhibits
differentiation. In lymphocyte development, c-myb is required for the proliferation of
thymocytes. C-myb over expression promotes the survival of T cells when treated with
dexamethasone by up regulating the anti-apoptotic bcl-2 gene. C-myb also regulates T
cell differentiation by binding to the RAG-2 gene that controls antigen receptor gene
rearrangement. Less is known about the role of c-myb in B lymphocyte development.
B lymphocytes are dependent on stromal cells for signals that regulate survival,
proliferation, and differentiation. We have developed an early pro-B cell line that is
dependent on stromal cells and IL-7 for continued survival and proliferation as a model
to study stromal cell/B cell interactions. These cells continue to proliferate in culture,
but have not been shown to differentiate in vitro. The work presented in this dissertation
will demonstrate that the pro-B cell line, C1.92, is characterized by c-myb expression.
Our work will determine the degradation kinetics of c-myb mRNA and protein in pro-B
cells and compare that with the known kinetics of c-myb in myeloid cells. Furthermore,
our work aims to determine whether stromal cells are responsible for maintaining c-myb
expression in pro-B cells and whether specific adhesion contacts are responsible for
this maintenance rather than stromal cell cytokines.

In addition, these studies will

determine whether c-myb is an intracellular regulator of proliferation and differentiation
in early pro-B cells, or an intracellular regulator of cell survival.

Finally, we will

investigate c-myb knockout mice to better understand how loss of c-myb expression
during embryonic development impacts fetal liver lymphopoiesis. We will also utilize a
mouse model deficient for a-myb to determine if one member of the myb family can
compensate for the loss of another member during fetal lymphopoiesis.
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X. RESEARCH OBJECTIVES
The main goal of the work presented in this dissertation is to understand the role of
c-myb in development of B lymphocytes. Current literature has clearly established a
putative role for c-myb in proliferation and differentiation of a vast array of
developmental cell types, including erythroid, myeloid, and T lymphoid cells. However,
there is a significant lack of fundamental information about the role of myb in B lymphoid
development.

This project will explore the normal expression patterns of myb in

developing B lymphocytes, determine if the hematopoietic microenvironment is able to
regulate the expression of myb during lymphopoiesis, and determine the role c-myb
plays in B lymphocyte maturation.

This dissertation will address the following

objectives:
1. Determine the normal expression patterns of c-myb in cells of the
developing B lineage. The following studies investigate the expression of cmyb in progenitor B cells. It is well documented that immature myeloid cells
require expression of c-myb early in development for normal proliferative
capacity, but also require c-myb to be downregulated for terminal differentiation.
This study will determine whether developing B lymphocytes also require
molecular changes in c-myb for normal proliferation and differentiation.

In

addition, this study will determine the half-life of c-myb mRNA and protein in
progenitor B cells and compare that with the known degradation kinetics of c-myb
in myeloid cells. Knowing the half-life of c-myb mRNA and protein will allow this
work to examine c-myb regulation at biologically relevant time points.
2. Determine whether stromal cells regulate the expression of c-myb in pro-B
cells. The role of bone marrow stromal cells as regulatory elements of B cell
development has been firmly established since they are known to regulate
several genes expressed by developing B lymphocytes.

These studies will

determine whether stromal cells maintain c-myb levels in highly proliferative, proB cells. Stromal cells regulate gene expression both by adhesion contacts and
by producing numerous cytokines.

We will determine whether c-myb mRNA

32

levels are maintained by specific stromal cell adhesion contacts or by stromal cell
derived cytokines.
3. Determine whether c-myb is an intracellular regulator of proliferation in
developing B lymphocytes. C-myb is known to be a regulator of proliferation in
myeloid, erythroid, and T cells. Several studies have also indicated that c-myb
regulates proliferation in transformed murine B cells.

These studies will

determine if c-myb regulates proliferation of B cell progenitors.
4. Determine whether c-myb is an intracellular regulator of differentiation in
developing B lymphocytes. Recently studies have demonstrated that c-myb
binds to the RAG-2 promoter (Kishi et al, 2002), suggesting that c-myb may
regulate maturation of pro-B cells. We will determine whether down regulation of
c-myb is required for gene rearrangement of heavy chain immunoglobulin genes.
5. Determine if c-myb is an intracellular regulator of cell survival in
developing B lymphocytes. C-myb is known to decrease the sensitivity of T
cells to cytokine withdrawal and protect them from apoptotic death. In addition,
c-myb over expression correlates with an increase in the expression of the antiapoptotic bcl-2 gene in T cells. We will determine whether down regulation of cmyb impacts pro-B cell survival and onset of apoptosis and cell death.
6. Evaluate B lymphopoiesis in myb knockout models. C-myb knockout mice
die at day 15 of embryogenesis due to loss of erythropoiesis in the fetal liver. We
will determine whether loss of c-myb during embryonic development affects B
cell development.

In addition, we will utilize animals with mutant a-myb to

determine if loss of another myb family member significantly alters B
lymphopoiesis in developing embryos.
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Chapter 2

Stromal Cells Regulate Expression of the Proto-oncogene C-myb in
Pro-B Cells
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ABSTRACT
B lymphocytes are continually produced throughout life in the bone marrow from
pluripotential hematopoietic stem cells. Lymphopoiesis is characterized by a series of
highly regulated genotypic and phenotypic changes that conclude with expression of
cell surface immunoglobulin on immunocompetent B cells.

Pro-B cell survival,

proliferation, and differentiation of B cell progenitors require a series of interactions with
fibroblastic stromal cells in the hematopoietic microenvironment.

However, specific

molecular mechanisms that regulate progression of B lymphoid development are poorly
understood. In this study we utilized a pro-B cell clone derived from 14-day fetal liver by
continuous in vitro passage in the presence of bone marrow stromal cells and
recombinant interleukin-7 (rIL-7). The cloned pro-B cell line remains dependent on the
presence of stromal cells for survival, does not form tumors in vivo, and reconstitutes B
lymphocytes in severe combined immunodeficient (SCID) mice. However, pro-B cells
clones are characterized by rapid and continuous proliferation and high expression
levels of the oncogene c-myb. Although several laboratories have proposed a role for
c-myb in myelopoiesis, virtually nothing is known about the physiologic function of cmyb in developing B lineage cells. Studies described here are aimed at determining
whether stromal cells regulate expression of c-myb in developing B lymphocytes. Pro-B
cells removed from stromal cells decreased c-myb mRNA and protein levels.
Experiments utilizing a transwell cell culture system demonstrated that stromal cell
adhesion was required for maintenance of c-myb expression. Down regulation of c-myb
correlated with genotypic maturation, progressive immunoglobulin gene rearrangement,
reduced proliferative capacity, and G0/G1 cell cycle blockade.
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INTRODUCTION
Hematopoiesis describes the continual development of functional blood cells
from pluripotential hematopoietic stem cells. Hematopoietic stem cells (HSC) retain
self-renewal capacity and the potential to generate cells of the erythroid, myeloid, and
lymphoid lineages. HSCs primarily reside in the bone marrow of post-natal mammals.
However, during embryonic development, hematopoietic stem cells are first found in the
aorta/gonad/mesonephros (AGM) region (Kincade, 1989). From the AGM region, HSCs
migrate into the liver of the developing embryo (Cumano, 2001; Moore 1970). It is
within the fetal liver that hematopoietic stem cells differentiate into committed lymphoid
and myeloid progenitor cells (Godin, 1999). Progenitor cells are distinguished from
HSCs by loss of self-renewal capacity and commitment to lineage specific development.
During postnatal life, lymphoid and myeloid progenitors differentiate through a series of
committed developmental stages to form non-proliferating effector cells. Effector cells
have a finite lifespan, and they are continuously regenerated from committed progenitor
cell populations in hematopoietic tissues.
The bone marrow is established as the primary site of hematopoiesis shortly
before birth, and this remains the primary hematopoietic organ throughout postnatal life
(Sabin, 1928; Micklem, 1966; Tavassoli, 1975).

The bone marrow is composed of

packed hematopoietic cells interspersed with a meshwork of non-hematopoietic cells
termed stromal cells. Fibroblastic stromal cells within the bone marrow are necessary
for hematopoiesis. Stromal cells support early cell development by providing adhesion
molecules that interact with receptors on developing hematopoietic cells (Johnson and
Dorshkind, 1986; Witte, 1987). In addition, stromal cells secrete cytokines into the
marrow environment including interleukin-7 (IL-7) and c-kit ligand (stem cell factor)
(Billips, 1992). These stromal cell products are necessary for continued lymphopoiesis
(Sudo, 1989; Dorshkind, 1990).
The Myb family of proteins is a group of transcription factors that bind DNA and
were first identified as part of avian myeloblastosis virus.

V-myb protein is a

constitutively active, mutated, and truncated form of C-myb, a product of the c-myb
proto-oncogene.

The c-myb proto-oncogene encodes a 75 kDa nuclear protein that
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binds to a consensus sequence of DNA [(T/C)AAC (T/G)G ] (Bidenkapp, 1988). C-myb
expression is high in the most immature hematopoietic cells, but levels of c-myb
decrease as immature cells differentiate into more mature progeny (Lipsick, 1996). Cmyb expression and regulation is necessary for normal hematopoietic development.
Inhibiting c-myb expression in hematopoietic cells using anti-sense oligonucleotides
causes growth arrest, while over-expressing c-myb results in leukemia (Westin, 1982
and Gewirtz, 1988). In 1982, Westin et al investigated c-myb expression in a human
promyelocytic leukemic cell line (HL-60). They determined that myeloid cells could be
held in a proliferative state when c-myb was over-expressed and induced to differentiate
when c-myb was downregulated (Westin, 1982). These data suggest a critical role for
c-myb in myelopoiesis. The development of a mouse model with a homozygous mutant
c-myb gene confirmed these data. Animals with homozygous interruption of c-myb
transcription were normal at day 13 of gestation, but by day 15 were severely anemic
and expired in utero. These animals exhibited a complete loss of erythropoiesis in the
fetal liver (Mucenski, 1991). These in vivo observations substantiate the role of c-myb
in maintenance of myelopoiesis. While the importance of c-myb in myelopoiesis has
been clearly established, the role of c-myb in lymphopoiesis has been suggested but
less defined.
Survival, proliferation, and differentiation of B lymphocytes depend on the
hematopoietic microenvironment provided in bone marrow (Dorshkind, 1990).
Expansion of pro-B cells is dependent on cytokines produced by bone marrow stromal
cells.

Interleukin-7 (IL-7) is a stromal cell derived cytokine that provides the major

proliferative stimulus for pro-B cells (Lee, 1989; Sudo,1989).

Several other bone

marrow derived cytokines, including insulin-like growth factor-1 (IGF-1), stem cell factor,
and flt-3 ligand, also regulate pro-B cell expansion by synergizing with IL-7 to maximize
pro-B cell proliferation (Gibson, 1993 and Ray, 1996). In addition to producing cytokines
that regulate proliferation stromal cells produce cytokines, including IGF-1, that regulate
differentiation.

Stromal cells also regulate the survival of pro-B cells.

Adhesion

contacts between stromal cells and pro-B cells control expression of the anti-apoptotic
bcl-2 gene, as well as the pro-apoptotic bax gene, in pro-B cells (Gibson, 1996). While
many of the interactions between stromal cells and pro-B cells have been elucidated,
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the total spectrum of genes and cytokines that influence pro-B cell survival, proliferation,
and differentiation has not yet been determined.
In this study, the role stromal cells play in pro-B cell development is further
investigated. These experiments are aimed at determining whether stromal cells are
responsible for c-myb expression and regulation in pro-B cells. The goals of this project
were to explore the normal expression patterns of c-myb in developing B lymphocytes,
to determine the expression kinetics of c-myb in pro-B cells, and to determine whether
the hematopoietic microenvironment regulated expression of c-myb in these cells. ProB cells cultured without stromal cells down regulated c-myb expression, withdrew from
cell cycle, and genotypically matured. These data demonstrate that c-myb expression
in pro-B cells is regulated by stromal cells.

MATERIALS AND METHODS
Cell Lines and Cytokines. A panel of pro-B cell lines was derived from normal Balb/C
mice.

Isolation of pro-B cell lines has previously been described in detail (Gibson,

1993). Briefly, fetal livers were removed from murine embryos at day 14 of gestation.
Fetal livers were dispersed into single cell suspension and the nonadherent cells were
passaged in the presence of a cloned bone marrow stromal cell line, S10, and 50 U/mL
of recombinant murine interleukin-7 (IL-7, Biosource International). The fetal liver cells
were then cloned at limiting dilution in the presence of S10 and IL-7.

One of the

resulting clones, C1.92, is utilized in these studies. C1.92 cells were maintained in αmodification of Eagle’s medium (α-MEM) supplemented with 5% fetal calf serum
(Summit, lot# 30P14), 1% penicillin/streptomycin, 1% l-glutamine, and 0.1% 2Mercaptoethanol in the presence of S10 and 50 U/mL of IL-7.
S10 stromal cells were a generous gift from Dr. Kenneth Dorshkind (University of
California).

Isolation and biological characteristics of S10 have been previously

described in detail (Collins and Dorshkind, 1987). S10 cells were maintained in α-MEM
media, supplemented as described above, and grown to confluence in 75 cm2 flasks.
They were passaged weekly by trypsinization (0.25%, GIBCO).
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Transwell Cell Cultures.

C1.92 cells were cultured for 24 hours in 6 well plates

directly in contact with a confluent adherent layer of S10 stromal cells or separated from
stromal cells in the same culture well by use of a cellulose 0.45 µm microporous
membrane transwell (Millicell-HA, Millipore, Bedford, MA).

All cultures were

supplemented with 50 U/ml IL-7. After 24 hours, cells were harvested, enumerated, and
cell viabilities were assessed.
Cell Counts and Viability assay. After incubation with direct stromal cell support,
without stromal cell support, or separated from stromal cell support by a transwell,
C1.92 cells were removed from culture, diluted with an equal volume of 0.4% trypan
blue (Sigma), and counted in a hemacytometer. Total cells in culture and viability were
calculated from hemacytometer counts.
RNA Isolation. After culture, 2x106 C1.92 cells were harvested, washed with PBS, and
frozen in liquid nitrogen. Total RNA was extracted using the SNAP RNA isolation kit
(Invitrogen).

After isolation, RNA was quantitated using a spectrophotometer and

quartz cuvettes.

0.1 µg of total RNA was amplified simultaneously for c-myb and

GAPDH using a one-step RT-PCR reaction (Qiagen). 0.1 µg of RNA was combined
with 1x Qiagen OneStep RT-PCR Buffer, 400 µM of each dNTP, 0.5 µg c-myb sense
primer, 0.5 µg c-myb antisense primer, 1µg GAPDH sense primer, 1 µg GAPDH
antisense primer, 2 µl Qiagen OneStep RT-PCR Enzyme Mix, 5 units RNase inhibitor,
and water to a total volume of 50 µl. C-myb specific primers used were: (sense primer)
5’-GAGCTTGTCCAGAAATATGGTCCGAAG-3’
GGCTGCCGCAGCCGGCTGAGGGAC-3’

and

(Biosource

(antisense

primer)

International).

5’-

GAPDH

amplification was used as a control for template integrity and normalization of data
utilizing

the

following

primers:

TGAAGGTCGGTGTGAACGGATTTGG-3’

and

ACGACATACTCAGCACCGGCCTCAC-3’

(Biosource

(sense
(antisense

primer)

5’-

primer)

International).

5’-

RT-PCR

amplifications were performed in a GeneAmp PCR System 9700 (Perkin Elmer Applied
BioSystems).

Reverse transcription was carried out at 50oC for 30 minutes.

polymerase was activated by heating for 15 minutes at 95oC.

DNA

Amplification was

o

performed for 30 cycles with denaturation at 94 C for 30 seconds, annealing at 60oC for
1 minute, and extension for 1 minute at 72oC with an additional 10 minute, 72oC
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extension added to the final cycle. PCR products were separated on 2% ethidium
bromide stained gels and visualized using Eagle Eye (Stratagene).
Protein Analysis. To evaluate the influence of stromal cells on C-myb protein levels,
C1.92 cells were maintained in normal culture conditions (directly in the presence of
S10 and IL-7), in transwell co-cultures, or in media alone. Protein was isolated from 106
pro-B cells in Laemmli’s buffer and separated on 8% denaturing polyacrylamide gels.
Gels were transferred to PVDF membrane and blocked for 30 minutes in PBS with 5%
dry milk at room temperature.

Blots were then probed with a primary monoclonal

mouse C-myb antibody (Clone 1.1, Upstate Biotechnology, 1 µg/ml) or monoclonal
mouse GAPDH (glucose-aldehyde-phosphate dehydrogenase) antibody (Research
Diagnostics, 0.5 µg/ml) in PBS with 3% milk overnight at 4oC. Blots were then washed
with one change of water and probed with a goat α-mouse Ig-HRP as the second
antibody for 2 hours at room temperature. Blots were washed with one quick wash of
water, one 15 minute wash of TBS with 0.1% Tween, and then 5 vigorous washes in
water at room temperature for one minute.

ECL plus (Amersham) was used as a

chemiluminescent reagent and then blots were exposed to Kodak X-OMAT film.
Densitometry analysis was done using Eagle Eye Software.
Determination of C-myb half-life.

To determine the half-life of c-myb mRNA, C1.92

cells were cultured for 1, 2, 4, 6, 12, and 24 hours in the presence of S10 stromal cells.
Cultures were treated with media alone, 10 µg/ml of the solvent DMSO, or 10 µg/ml of
actinomycin D.

RNA was isolated from cultured cells and RT-PCR (as described

above) was utilized to determine the rate of c-myb mRNA degradation. To determine
the half-life of C-myb protein, C1.92 cells were cultured in the presence of S10 stromal
cells for 15, 30, 60, and 90 minutes. Cultures were treated with media alone, 10 µg/ml
of the solvent ethanol, or with 10 µg/ml of cyclohexamide.

Degradation of C-myb

specific protein from treated cells was analyzed by Western Blotting, with GAPDH as an
internal protein loading control (as described above).
Intracellular Fluorescent Staining. For intracellular C-myb staining, 106 C1.92 cells
were harvested after being cultured with or without stromal cells for 0 or 8 hours. Cells
were washed with ice-cold PBS containing 0.1% heat inactivated fetal bovine serum
(PBS/FBS). Cells were aspirated to dryness, resuspended in 1 ml of paraformaldehyde
55

buffer and fixed for 10 minutes at 4oC. Cells were then washed with PBS/FBS and
resuspended in 25µl of permeabilization buffer. 20 µg of C-myb specific antibody (UBI,
Clone 1.1) or IgG2a isotype antibody (Southern Biotechnology) were added to
suspension and incubated for 30 minutes at 4oC.

Cells were then washed with

PBS/FBS and incubated for 30 minutes at 4oC with a secondary goat α-mouse Ig-FITC.
After 2 washes of permeabilization buffer, cells were resuspended in 1 ml of
permeabilization buffer and analyzed using a flow cytometer (FACScan; Becton
Dickinson).
DNA Isolation and Ig gene rearrangement status. DNA was isolated from 106 C1.92
cells using the Easy-DNA isolation kit (Invitrogen). DNA was RNase treated to remove
contaminating RNA and resuspended in 100 ml of Tris-EDTA (pH 8). 500 ngs of DNA
were used in a PCR reaction (Promega) to determine immunoglobulin (Ig) gene
rearrangement status. The Ig heavy chain is assembled from a variable (V) region, a
diversity (D) region, a joining (J) region, as well as a constant region (Yancopoulos,
1986).

These loci are separated from one another in the germline by intervening

sequences, and are joined together upon B cell differentiation. Ig heavy chain gene
rearrangement status was determined using primer sets (Hardy, 1991) complementary
to the intervening sequence between the V and D section of the heavy chain gene
(using primers DFL16.1; 472 bp amplicon) and between the D and J section of the heavy
chain gene (using primers JH1; 1227 bp amplicon). The sequence of primer sets was
as follows: DFL16.1 (sense primer) – 5’-GCCTGGGGAGTCACTCAGCAGC-3’;
(antisense primer) – 5’-GTGTGGAAAGCTGTGTATCCCC-3’ and
JH1 (sense primer) - 5’- CCCGGACAGAGCAGGCAGGTGG-3’ and
(antisense primer) –5’-GGTCCCTGCGCCCCAGACA-3’. Amplification was performed
for 35 cycles with denaturation at 95oC for 1 minute, annealing at 63oC for 3 minutes,
and extension for 4 minutes at 72oC with an additional 15-minute extension added to
the final cycle.
rearrangement.

Loss of a DFL16.1 or a JH1 amplicon was indicative of gene
DNA from identically prepared S10 was used to confirm germline

configuration.
GAPDH

((sense

primer)

5’-TGAAGGTCGGTGTGAACGGATTTGG-3’

(antisense

primer) 5’-ACGACATACTCAGCACCGGCCTCAC-3’)) amplification was used as a
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control for template integrity and normalization of data. PCR products were separated
on 2% ethidium bromide stained gels and visualized using Eagle Eye (Stratagene).
Proliferation assay. Following culture with direct stromal cell support, indirect stromal
cell support, or no stromal cell support, 105 viable C1.92 cells were allocated in 96 well
plates coated with S10 and 200 µl of α-MEM media. Where indicated, IL-7 (50 U/ml)
was added to the cultures. Cells were cultured over night for 18 hours, and then pulsed
with 1 µCi 3H-TdR/well. After 6 more hours of culture, cells were harvested onto glass
wool fiber strips with an automated cell harvester (Cambridge Instruments, Boston, MA).
Radioactive incorporation was determined by liquid scintillation counting in an aqueous
fluor (Biosafe-II; Research Products International). Each treatment was repeated in
triplicate.
Cell Cycle Analysis.

C1.92 cells were cultured with or without stromal cells as

previously described. 106 cells were fixed in 70% EtOH (at –20oC) and treated with 20
µg RNase A (Sigma) at 37oC for 30 minutes. Cells were then stained with 50 µg/mL
propidium iodide (PI) (Sigma) to evaluate DNA content. PI stained cells were evaluated
using a flow cytometer (FACScan; Becton Dickinson) and analyzed using ModFit
Software.

RESULTS
Expression of c-myb in pro-B cells. C1.92 pro-B cells (Fig. 1a) were cultured in the
presence of S10 stromal cells and exogenously added IL-7 (50 U/ml). After culture,
expression of c-myb mRNA was evaluated using RT-PCR amplification. As shown in
Fig. 1b, C1.92 cells expressed c-myb mRNA. Amplification of GAPDH was used as a
control to ensure template integrity. To further confirm the presence of c-myb in pro-B
cells, C1.92 cells were assayed for C-myb protein by western blot. As shown in Fig 1c,
C1.92 cells expressed C-myb protein that was confirmed by immunohistochemistry and
FACS analysis (figure 4b). C1.92 pro-B cells expressed both mRNA and protein for the
proto-oncogene c-myb. S10 stromal cells had no detectable mRNA or protein for c-myb
(Fig. 1b and 1c).
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A.

B.

C.
C1.92

S10

C1.92

S10

c-myb
gapdh

Figure 1. Characterization of C1.92 Pro-B Cell Clone. (A) Cytospin preparation of
C1.92 cells in vitro stained with Jenner-Giemsa. Viewed at 100x magnification. (B) RTPCR amplification of c-myb in C1.92 cells. C-myb amplicon is approximately 500 bp.
GAPDH was used as a control to ensure template integrity.

GAPDH amplicon is

approximately 300 bp. (C) C-myb protein expression in C1.92 cells by Western Blot
analysis.
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C-myb mRNA half-life.

In order to accurately evaluate changes in c-myb mRNA

levels, it was necessary to determine the half-life of c-myb in pro-B cells. To determine
the half-life of c-myb mRNA, C1.92 cells were cultured for 1, 2, 4, 6, 12, or 24 hours in
the presence of S10 stromal cells. Cultures treated with media alone or with 10 µg/ml of
the solvent DMSO exhibited no change in c-myb expression throughout the time course
(Figure 2). C1.92 cells cultured with 10 µg/ml of actinomycin D had a 50% decrease in
c-myb mRNA expression after 6 hours of treatment. After 24 hours of treatment, c-myb
mRNA levels decreased to almost undetectable levels (Figure 2). Because the c-myb
mRNA seemed to be so stable, it was necessary to confirm the length of the half-life
using a different set of RT-PCR primers.

Primers were designed in a completely

different area (over exon 9A) of the c-myb mRNA message and RT-PCR amplification
was performed. Amplification of actinomycin D treated mRNA with the second set of
primers confirmed that the half-life of the mRNA message is long-lived, with 50% of the
message being degraded at approximately 11 hours (data not shown). Cell viabilities
were determined at every time point for all treatments. No changes in cell viabilities
were noted.
C-myb protein half-life. To determine the half-life of C-myb protein, C1.92 cells were
cultured in the presence of S10 stromal cells for 15, 30, 60, and 90 minutes. Cultures
treated with media alone or with 10 µg/ml of the solvent ethanol exhibited no change in
C-myb expression, as determined by Western Blot, throughout the time course (Figure
3). C1.92 cells cultured with 10 µg/ml of cyclohexamide had a 50% reduction in C-myb
protein within 60 minutes of treatment (Fig 3). Cell viabilities were assessed at each
time point for every treatment group. No changes in cell viability were seen.
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Figure 2. Half-life of C-myb mRNA in Pro-B Cells. C1.92 pro-B cell lines were
expanded on S10 stromal cells. After 24 hours of culture, C1.92 cells were treated with
10 µg/ml of DMSO (), 10 µg/ml of actinomycin D (), or left untreated (). MRNA
was isolated at 0, 2, 4, 6, 12, or 24 hours post treatment. Data shown is one of five
replicate experiments.
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Figure 3. Half-life of C-myb Protein in Pro-B Cells. C1.92 pro-B cell lines were
expanded on S10 stromal cells for 24 hours. Pro-B cell lines were treated with 10 µg/ml
of ethanol (), 10 µg/ml of cyclohexamide (), or left untreated (). Data shown is
one of five replicate experiments.
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Stromal cell regulation of c-myb. It is well documented that stromal cells regulate
gene expression in developing B lineage cells.

We determined whether stromal cells

regulated the expression of the proto-oncogene c-myb in IL-7 dependent pro-B cells.
C1.92 cells were cultured for 0, 2, 4, or 6 hours in cell culture medium and IL-7 in the
absence of stromal cells. At each time point, RNA was isolated and amplified for c-myb
and GAPDH in an RT-PCR reaction. Within 6 hours, c-myb mRNA had decreased to
50% of control levels (Fig 4a).

To determine whether C-myb protein was also

decreased, C1.92 cells were cultured for 8 hours in cell culture media and IL-7 with no
stromal cell support. After 8 hours, cells were labeled with a C-myb specific FITC
tagged antibody and analyzed by FACS analysis. Within 8 hours, C-myb protein had
decreased by 50 % in pro-B cells grown without stromal cell influence (Fig 4b). This
was also confirmed by Western Blot analysis.
Stromal cell adhesion contacts maintain c-myb expression. Stromal cells provide
both adhesion contacts and cytokine support that are necessary for B lymphopoiesis.
Previous data indicated that stromal cells are necessary for maintenance of c-myb
expression; however it was necessary to determine if stromal cell cytokines or actual
adhesion interactions with stromal cells were responsible for maintaining c-myb levels in
pro-B cells. C1.92 cells were cultured directly on a confluent stromal cell layer (control,
Fig 5a and Fig 5b) or separated from the stromal cell layer by a cellulose transwell
membrane (transwell, Fig 5a and 5b). C1.92 cells were exposed to soluble factors
released by stromal cells, but prevented from physical interaction with stromal cells in
transwell cultures.

This dissected the influence of released soluble factors from

membrane bound proteins.

As shown in Figure 5, pro-B cells separated from the

stromal cell layer via a transwell had a significant decrease in c-myb mRNA as well as
C-myb protein within 24 hours. This indicates that stromal cell adhesion contacts are
primarily responsible for maintenance of C-myb in developing B lineage cells.
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Figure 4. Stromal Cells Regulate C-myb Expression. (A) C1.92 cells were cultured
for 0, 2, 4, or 6 hours in cell culture medium and IL-7 in the absence of stromal cells.
C1.92 cells were harvested and RNA isolated. RNA for c-myb and GAPDH was then
amplified by RT-PCR.

C-myb mRNA was normalized to GAPDH expression using a

Stratagene Eagle Eye. C-myb mRNA was decreased by 50% within 6 hours. (B) C1.92
cells were cultured in the absence of stromal cells for 8 hours. After 8 hours, C1.92
cells were stained with a C-myb specific antibody to determine intracellular protein
expression.
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Figure 5. Stromal Cells Regulate C-myb Expression via Adhesion Contacts. (A)
C1.92 cells were cultured for 24 hours directly in contact with stromal cells or separated
from stromal cells in the same culture well by use of a transwell. Cells were harvested
and total RNA isolated. RNA for c-myb and GAPDH was amplified by RT-PCR reaction.
After 24 hours c-myb mRNA levels were decreased by approximately 80%. (B) C-myb
protein levels were also analyzed by Western Blotting.
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Decreased C-myb is associated with impaired proliferative capacity.

It is well

documented that decreases in c-myb correlate with inhibition of proliferation in myeloid
cells. In order to determine whether the decrease in c-myb levels observed when pro-B
cells were cultured in transwells correlated with decreased pro-B cell proliferation,
tritiated thymidine uptake was assayed. Pro-B cells grown in direct contact with stromal
cells (control, Fig 6) exhibited a proliferative response after exposure to IL-7.

In

contrast, pro-B cells that had decreased c-myb levels due to loss of stromal cell contact
showed a significant impairment in the ability to respond to IL-7 (transwell, Fig 6).
Impaired proliferative capacity was due to a block in cell cycle. We wanted to
determine if the observed inhibition of proliferation was due to alterations in pro-B cell
cycle. Normally, approximately 65% of pro-B cells in culture with stromal cell support
are in the G0/G1 phase of the cell cycle with 30% in the G2/M phase and 5% in the S
phase. However, after 24 hours of culture with a transwell, C1.92 cells exhibited a
failure to exit the G0/G1 phase of the cell cycle. Greater than 95% of the cells were in
the G0/G1 phase of the cell cycle with only 3% in the G2/M phase and less than 2% in
the S phase (Fig 7). These data indicate that impairment in cell cycle, associated with a
decrease in c-myb expression levels, is the result of altered cell cycle kinetics.
Loss of c-myb expression correlated with Ig heavy chain gene rearrangement.
Exit from the cell cycle in developing B lineage cells is often accompanied by
differentiation into a more mature cell. To investigate the possibility that pro-B cells with
down regulated c-myb levels were differentiating, Ig heavy chain gene rearrangement
status was evaluated.

C1.92 cells are early pro-B cells, thus they have not yet

rearranged either the D-J or V-DJ loci and they remain in germline configuration while in
culture with direct stromal cell contact (control, Fig 8). However, when C1.92 cells are
cultured in a transwell for 24 hours, D-J rearrangement of the Ig heavy chain gene
occurs as indicated by the loss of an amplicon (transwell, Fig 8). V-DJ rearrangement
does not occur, and this loci is retained in germline configuration. These data indicate
that loss of c-myb, which occurs when C1.92 cells are cultured without direct stromal
cell support, is accompanied by genotypic maturation.
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Figure 6. Proliferative Response of Pro-B Cells. C1.92 cells were cultured directly
in the presence of stromal cells or separated from direct stromal cell contact via a
transwell for 24 hours. After culture, 105 live C1.92 cells were plated into 96 well plates
with S10 stromal cells for 18 hours. The cytokine IL-7 (50 U/ml) was added where
indicated.

After 18 hours, 1µCi of 3H-TdR was added to each well.

Cells were

harvested 6 hours later. Quantitation of incorporated 1µCi of 3H-TdR is presented as
counts per minute (CPM) +/- SEM for 3 replicate cultures.
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Figure 7. Altered Cell Cycle Kinetics. C1.92 cells were cultured for 24 hours with
direct stromal cell contact or separated from stromal cell adhesion contacts by a
transwell membrane. After 24 hours, cells were harvested and stained with propidium
iodide (PI). To determine DNA content, PI incorporation was measured using FACS
analysis and ModFit software. Data for one of 3 replicate experiments is shown.
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Figure 8. Down Regulation of C-myb is Associated with Pro-B Cell Differentiation.
C1.92 cells were cultured in direct contact with stromal cells or separated from stromal
cell contact via a transwell for 24 hours. DNA was isolated from 106 pro-B cells. RTPCR
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DISCUSSION
Early

pro-B

cell

development

is

dependent

on

the

hematopoietic

microenvironment found in the bone marrow (Dorshkind, 1990). This niche provides
regulatory signals that are critical for B lymphopoiesis. Fibroblastic stromal cells within
the bone marrow microenvironment supply a vast majority of these regulatory signals
through cell adhesion contacts and cytokine stimulation.

B cell progenitors must

express and/or repress various genes during their maturation process. Failure to tightly
regulate gene expression can halt B cell development, leading to hematopoietic defects.
It is known that the regulation of some early lymphoid genes is intrinsic to the
developing cell, while other genes are regulated by the stromal cell microenvironment.
However, the mechanism regulating many other genes expressed by developing
lymphocytes is completely unknown. One gene highly expressed in early hematopoietic
cells is the proto-oncogene c-myb (Lipsick, 1996).

The aims of this work are to

determine if early pro-B cells express c-myb and to determine if the hematopoietic
microenvironment is involved in regulating c-myb expression in developing B
lymphocytes. Data presented here demonstrate that c-myb is expressed in an IL-7,
stromal cell dependent pro-B cell line and suggest that expression of c-myb is regulated
by stromal cell adhesion contacts.
This report is not the first to demonstrate the important relationship between
stromal cells and developing B lymphocytes. Many stromal cell derived cytokines are
known to impact the expansion of B cell progenitors.

The stromal cell secreted

cytokine IL-7, in conjunction with stromal cell derived IGF-1 and Flt3 ligand, are the
major proliferative stimuli provided to early developing B cells (Gibson, 1993). Stromal
cell derived factor-1 (SDF-1) is another mediator constitutively expressed by bone
marrow derived stromal cells that stimulates the proliferation of B cell progenitors. The
majority of mutant mice harboring a targeted disruption in the SDF-1 gene expire in
utero at day 18.5 of embryogenesis, and mutants that survived had significantly
decreased numbers of pro-B and pre-B cells (Nagasawa, 1996). Stromal cell derived
Flt-3 ligand and IGF-1 not only affect early B cell expansion, but they also have
important roles in B lineage differentiation (Dorshkind, 1990 and Ray, 1996). In addition
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to releasing cytokines that aid in B cell expansion and maturation, stromal cells are
involved in providing survival signals as well. Expression of both pro- and anti-apoptotic
genes in developing B lymphocytes is regulated by stromal cells, including bcl-2 and
bax (Gibson, 1996).

Stem cell factor (kit ligand) is produced by stromal cells and

serves as a ligand for the tyrosine kinase receptor c-kit expressed on hematopoietic
cells. The importance of this stromal cell/B cell interaction was evident when murine
models deficient in c-kit or kit ligand resulted in prenatal lethality between days 13 and
15 of gestation due to loss of fetal liver hematopoiesis (Russel, 1979). Although many
of the regulatory signals and stromal cell/B cell interactions have been reported, the full
complement of genes that stromal cells may regulate, and the specific mechanisms by
which stromal cells exert this regulation, are largely unknown.
Although c-myb has been shown to be critical in the development of erythroid
and myeloid precursors, less work has been done on the role of c-myb in the normal
development of lymphocytes. Because the loss of c-myb results in embryonic lethality,
it is difficult to investigate the regulation of c-myb in developing B lymphocytes. This
problem was circumvented in studies of erythroid and myeloid cells using an in vitro cell
model. We have developed a cloned fetal liver pro-B cell line that is dependent on
stromal cells and IL-7 for continued survival and proliferation (Gibson, 1993).

This

population of pro-B cells continues to proliferate in culture in the presence of stromal
cells and IL-7, but does not differentiate. Westin et al previously demonstrated high
expression levels of the proto-oncogene c-myb hold myeloid cells in a proliferative state
and inhibit differentiation. Using Western Blot and RT-PCR, we determined that high
levels of mRNA and protein for the proto-oncogene c-myb characterize C1.92 cells.
Therefore, we have developed an in vitro model that will be useful to study the
regulation of c-myb in an IL-7, stromal cell dependent pro-B ell line.
The half-life of c-myb mRNA and protein has not yet been reported for
developing B lineage cells. In order to investigate c-myb regulation, it was necessary to
determine the degradation kinetics of c-myb mRNA and protein in pro-B cells. Our
experiments with actinomycin D and cyclohexamide revealed a long half-life for c-myb
mRNA (11hours) with a much shorter half-life for C-myb protein (less than 1 hour).
Although not reported in the literature, the half life of c-myb in pro-myelocytes is
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approximately 1 hour for both the mRNA and the protein (Westin, personal
communication). While the protein half-life for c-myb in pro-B cells is similar to that
reported for myeloid cells, the mRNA half-life of c-myb is much longer in pro-B cells
than in pro-myelocytes. These data give us a time frame within which we can conduct
further experiments at biologically relevant times.
Because C1.92 are continuously grown in the presence of stromal cells, and
stromal cells have previously been shown to regulate other genes involved in the
proliferation and differentiation of B lymphocytes, we hypothesized that the
hematopoietic microenvironment is able to regulate the expression of c-myb in pro-B
cells. In the present report, we show that c-myb is down regulated when C1.92 cells are
grown in culture media alone without stromal cell support. Removal of pro-B cells from
stromal cells and IL-7 for only 6 hours resulted in c-myb mRNA levels that were less
than 50% of control levels. Immunofluorescent staining for intracellular C-myb protein
supported mRNA data, revealing a decrease in protein levels within 8 hours after
removal from S10 and IL-7. Western blots were also performed to determine C-myb
protein levels. These studies confirmed observations made from immunohistochemistry
data; C1.92 cells removed from S10 and IL-7 for 24 hours showed decrease levels of Cmyb protein, to almost undetectable levels.

These data are particularly interesting

because stromal cell regulation of c-myb expression has not been considered
previously.

These data are the first to suggest that c-myb expression, like the

expression of many other pro-B cell genes, is under the control of stromal cells. This
indicates that stromal cells are necessary to maintain the expression of c-myb in
developing B lineage cells.
It is known, however, that stromal cells provide both cytokine support and cell
adhesion contacts to immature B cells. We utilized a transwell culture system to
determine if stromal cell cytokines (such as IL-7, IGF-1, SDF-1, or KL) or stromal cell
adhesion contacts (such as VCAM-1, CD44, fibronectin, or hyaluronate) are responsible
for the maintenance of c-myb expression. The transwell culture system prohibits
stromal cell/pro-B cell contact, but still allows pro-B cell exposure to stromal cells
cytokines. We determined that stromal cell adhesion contacts are largely responsible
for high levels of c-myb expression in pro-B cells. At 24 hours, c-myb mRNA and
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protein expression decreased in pro-B cells that did not have direct stromal cell
interaction. However, c-myb expression was not completely ablated. This indicates
that stromal cell contacts are largely responsible for c-myb expression in pro-B cells, but
not solely responsible. Extending the experiments to 48 hours may reveal a complete
loss of c-myb, but the cell viability of transwell cultures begins to decrease after 24
hours in culture therefore complicating data analysis. It remains possible that that both
stromal cell adhesion contacts and stromal cell cytokines regulate c-myb expression.
We also determined that the down-regulation of c-myb expression following
culture in the transwell system correlated with alterations in the proliferative response of
C1.92 cells.

C1.92 cells cultured in the transwell for 24 hours exhibited a loss of

responsive to their major proliferative stimulus, IL-7. In addition, there were a greater
number of pro-B cells in the G0/G1 phase of the cell cycle and correspondingly fewer
cells in the G2/M and S phases of the cell cycle. This was due either to a slower rate of
progression through the cell cycle or an inability to exit the G0/G1 phase. The decrease
of c-myb mRNA and protein in pro-B cells corresponds with alterations in proliferative
capacity and cell cycle progression.
The finding that pro-B cells exited the cell cycle when c-myb levels decreased
was intriguing.

The observed inhibition of proliferation and cell cycle suggest two

possible fates for C1.92 cells. Pro-B cells may be exiting the cell cycle in preparation
for apoptosis. However, this idea is not supported by our experimental data. Following
culture transwells separated from stromal cells, the viability of C1.92 cells is not different
from that of control cells. In addition, propidium iodide analysis did not reveal increases
in C1.92 cells with less than 2N DNA, indicative of cell death (data not shown). These
data indicate that, after 24 hours of culture in transwells, C1.92 cells are not initiating
significant apoptosis. The second possibility is that the pro-B cells exit cell cycle prior to
differentiation. In normal B lineage development, pro-B cell differentiation into pre-B
cells is accompanied by a corresponding decrease in cell cycle progression.

In

addition, this maturation is also accompanied by rearrangement of the immunoglobulin
(Ig) heavy chain gene. As pro-B cells become immature B cells, they must generate B
cell receptors. This is accomplished through systematic rearrangements of the Ig heavy
chain gene, commencing with rearrangement of the D-J loci followed by rearrangement
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of the V-DJ loci. Ig gene rearrangements were evaluated using PCR amplification of
germline Ig heavy chain gene sequence. PCR analysis of the intervening sequences
between the D and J and V and D segments of the Ig heavy chain gene revealed that
gene rearrangement is occurring at the D-J loci after transwell culture as shown in figure
8. These data suggest an association between the down regulation of c-myb and pro-B
cell maturation.
Taken together, these data provide the basis for expanding the role that stromal
cells play in B lymphopoiesis. As early immature cells, pro-B cells require contact with
stromal cells for their continued survival, proliferation, and differentiation. Along with
several other events described above, this stromal cell contact maintains a high level of
c-myb expression in pro-B cells. As pro-B cells mature to express Ig (pre-B cells), they
lose dependence on stromal cell contact.

This loss of stromal cell influence is

accompanied by a decrease in c-myb expression, a corresponding decrease in
proliferation, an inhibition of progression through the cell cycle, and rearrangement of
the D-J loci of the heavy chain gene indicative of maturation. This suggests that c-myb
expression may be one of the many ways that stromal cells guide immature B cells
through maturation and differentiation.
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Chapter 3

C-myb Regulates Proliferation and Differentiation of Murine Pro-B
Cells
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ABSTRACT
The expansion and maturation of a finite quantity of pluripotient stem cells into
differentiated progeny is termed hematopoiesis.

Pluripotent stem cells divide and

mature into all blood cell types. Typically, stem cells are relatively unresponsive to
cytokine influence because their proliferation and differentiation must be restrained in
order to prevent stem cell depeletion. The stem cell compartment must maintain stable
numbers of highly proliferative progenitor cells and must produce progeny capable of
maturation into end effector cells.

The molecular events that regulate cell fate

determinations in hematopoietic cells are largely uncharacterized. One protein family
important in regulating cell fate decisions is the myb family of proteins. In particular, cmyb has been shown to be critical in the development of erythroid and myeloid
precursors. Much of the erythroid and myeloid work has been accomplished using an in
vitro cell model since in vivo mutations of c-myb result in embryonic lethality. Less
work, however, has been done on the role of c-myb in the normal development of
lymphocytes due to the lack of an appropriate model of B cell development. Studies in
this report describe development of a system in which c-myb expression in pro-B cells
can be manipulated while pro-B cells remain in co-culture with stromal cells. In addition,
this work determines that c-myb is an intracellular regulator of proliferation and
differentiation in early B cell progenitors, but does not impact their cell survival. These
data clearly establish the role of c-myb in the development of stromal-cell dependent
pro-B cells.
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INTRODUCTION
Hematopoiesis is the process by which a limited number of multipotient stem
cells mature and expand to form differentiated progeny. The majority of stem cells are
quiescent and relatively unresponsive to cytokine influence.

The proliferation and

differentiation of stem cells is tightly regulated in order to prevent exhaustion of the stem
cell compartment. The function of the stem cell compartment is two-fold: maintenance
of stable numbers of multipotent progenitor cells and differentiating into mature effector
cells having a finite lifespan (Till and McCulloch, 1961; Metcalf and Moore, 1971). In
order for stem cells to mature into effector cells, they must enter the cell cycle after
extrinsic stimulation by cytokines (Bradford, 1997). After entering the cell cycle, the
stem cell progresses through a highly proliferative, cytokine responsive progenitor cell
stage. Progenitor cells undergo a sequence of genetic expression and repression that
affects self-renewal and lineage specific differentiation.

Molecular mechanisms that

regulate self-renewal and differentiation of developing hematopoietic cells have not
been well defined.
One family of proteins known to modulate lineage specific events in
hematopoiesis is the Myb family of proteins. Myb family members are DNA binding
proteins that play critical roles in cell fate determinations and maintenance of
differentiation status in many developmental systems (Gewirtz and Calabretta, 1988;
Clarke MF, 1988; Patel G, 1993; Mucenski ML, 1991). Myb family members have been
highly conserved throughout evolution, and have been found in most every organism
studied.

Three related Myb gene family members have been identified in vertebrates;

these include A-myb, B-myb, and C-myb. In particular, the proto-oncogene c-myb is
essential for definitive hematopoiesis in murine models (Mucenski, 1991).

The c-myb

proto-oncogene encodes a 75 kDa nuclear protein that binds to a consensus sequence
of DNA [(T/C)AAC (T/G)G ] (Gonda, 1983, Westin, 1982 and Bidenkapp, 1988). C-myb
is expressed at high levels in immature, highly proliferative hematopoietic cells, but
levels of C-myb decrease as immature cells differentiate into more mature progeny
(Westin, 1982; Gonda and Metcalf, 1984; Craig and Bloch, 1984; Sheiness and
Gardinier, 1984).

C-myb facilitates self-renewal of pro-myelocytes by impeding exit
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from, and maintaining these cells in, cell cycle. Overexpression of c-myb or failure to
downregulate c-myb during development is thought to lead to myelocytic leukemia.
These data suggest that downregulation of c-myb is required for terminal differentiation
of myeloid cells. However, the role of c-myb in developing B lineage cells has not been
investigated.
B lymphocyte development occurs in the bone marrow, and is characterized by
progressive rearrangement and expression of immunoglobulin heavy and light chain
genes (Yancopoulos, 1986). Newly formed B lymphocytes are a population of rapidly
renewed cells in the bone marrow of mammals (Landreth, 1981). The steady state
production of B lymphocytes depends on lineage specific gene expression, alternative
lineage gene repression, and a cascade of regulatory cytokines. Considerable progress
has been made in defining both intracellular and extracellular signals that regulate the
development of B lymphocytes. However, many other events regulating B lymphocyte
development are poorly understood. In particular, the role of the proto-oncogene cmyb, which is expressed in highly proliferative, early pro-B cells, is not clearly defined.
The function of c-myb is well defined in myeloid cell development, and progress is being
made in determining myb’s role in T cell development (Allen, 1999, Westin, 1982,
Mucenski, 1991, Gewirtz and Calabretta, 1988).

However, the role of c-myb in B

lymphocyte development is virtually unknown.

B lymphocyte development is a

complicated system to investigate because early B lymphocytes do not develop
independently. Instead, they develop in conjunction with non-hematopoietic stromal
cells located in the bone marrow.
Previous data from this lab demonstrated that stromal cells regulate c-myb
expression in pro-B cells. In this manuscript, we further delineate the role of c-myb in
the survival, proliferation, and differentiation of pro-B cells.

Our studies aimed to

determine whether c-myb is an intracellular regulator of survival, differentiation, and/or
proliferation in pro-B cells. Downregulation of c-myb in C1.92 pro-B cells resulted in
genotypic maturation, progressive immunoglobulin gene rearrangements, and impaired
proliferative capacity. However, c-myb downregulation in pro-B cells did not directly
impact cell survival.

Taken together, these data demonstrate that proliferation and
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differentiation of pro-B cells depends on expression and regulation of c-myb whereas
pro-B cell survival is c-myb independent.

MATERIALS AND METHODS
Cell Lines and Cytokines. A panel of pro-B cell lines was derived from normal Balb/C
mice. Fetal livers were removed from murine embryos at day 14 of gestation. Fetal
livers were dispersed into single cell suspension and the non-adherent cells were
passaged in the presence of a cloned bone marrow stromal cell line, S10, and 50U/mL
of recombinant murine interleukin-7 (IL-7). The fetal liver cells were then cloned at
limiting dilution in the presence of S10 and IL-7. One of the resulting clones, C1.92, is
utilized in these studies.
medium

(α-MEM)

C1.92 cells are maintained in α-modification of Eagle’s

supplemented

with

5%

fetal

calf

serum

(Summit),

1%

penicillin/streptomycin, 1% l-glutamine, and 0.1% 2-Mercaptoethanol in the presence of
S10 and 50U/mL of IL-7. S10 stromal cells were a generous gift from Dr. Kenneth
Dorshkind (University of California). Isolation and biological characteristics of S10 have
been previously described in detail (Johnson, 1986). S10 cells were maintained in αMEM media supplemented as described above and grown to confluence in 75 cm2
flasks. They were passaged weekly by trypsinization (0.25%, GIBCO).
Downregulation of C-myb. C-myb expression was abrogated using two methods.
Non-specific downregulation was accomplished using DMSO (dimethylsulphoxide).
DMSO was added directly to culture conditions at varying concentrations including
0.5%, 0.75%, 1.0%, 1.25% and 1.5%. Cultures were treated for varying times: 2 hours,
6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, and 144 hours. Specific Cmyb

downregulation

was

accomplished

by

using

antisense

oligonucleotides

complementary to the start site of the c-myb mRNA sequence.

Antisense

oligonucleotides (5’-GTTGAGTGGGGCGCCCATCATCGC-3’ with phosphorothioated
backbone) (Biosource International and Integrated DNA Technologies, Inc.) were added
to pro-B cell cultures at a concentration of 14 µM for 60 hours. As a control, scrambled
oligonucleotides (5’-CGGTCCTCACGGTAGCAGGTGTCG-3’ with phosphorothioated
backbone) were also added to pro-B cell cultures.
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Scrambled oligonucleotides

contained the same A/T and G/C content as antisense oligos. PBS was also added to
cultures as a control since antisense and scrambled oligonucleotides were reconstituted
in PBS.
Cell Counts and Viability assay.

After treatment with DMSO or oligonucleotides,

C1.92 cells were removed from culture, diluted with an equal volume of 0.4% trypan
blue (Sigma), and counted in a hemacytometer. Both total cells and viable cells in
culture were calculated from hemacytometer counts.
RNA Isolation. After culture with DMSO or oligonucleotides, 2x106 C1.92 cells were
harvested, washed with PBS, and frozen in liquid nitrogen. Total RNA was extracted
using the SNAP RNA isolation kit (Invitrogen). After isolation, RNA was quantitated
using a spectrophotometer and quartz cuvettes. 0.1 µg of total RNA was amplified
simultaneously for c-myb and GAPDH using a one-step RT-PCR reaction (Qiagen). 0.1
µg of RNA was combined with 1x Qiagen OneStep RT-PCR Buffer, 400 µM of each
dNTP, 0.5 µg c-myb sense primer, 0.5 µg c-myb antisense primer, 1µg GAPDH sense
primer, 1 µg GAPDH antisense primer, 2 µl Qiagen OneStep RT-PCR Enzyme Mix, 5
units RNase inhibitor, and water to a total volume of 50 µl.
used

were:

(antisense

(sense

primer)

primer)

C-myb specific primers

5’-GAGCTTGTCCAGAAATATGGTCCGAAG-3’

5’-GGCTGCCGCAGCCGGCTGAGGGAC-3’

and

(Biosource

International). GAPDH amplification was used as a control for template integrity and
normalization

of

data

utilizing

the

following

TGAAGGTCGGTGTGAACGGATTTGG-3’

primers:

and

ACGACATACTCAGCACCGGCCTCAC-3’

(Biosource

(sense

(antisense

primer)

primer)

International).

5’5’-

RT-PCR

amplifications were performed in a GeneAmp PCR System 9700 (Perkin Elmer Applied
BioSystems).

Reverse transcription was carried out at 50oC for 30 minutes.

polymerase was activated by heating for 15 minutes at 95oC.

DNA

Amplification was

performed for 30 cycles with denaturation at 94oC for 30 seconds, annealing at 60oC for
1 minute, and extension for 1 minute at 72oC with an additional 10 minute, 72oC
extension added to the final cycle. PCR products were separated on 2% ethidium
bromide stained gels and visualized using Eagle Eye (Stratagene).
Protein Analysis. To evaluate the influence of DMSO or antisense oligonucleotides
on C-myb protein levels, C1.92 cells were maintained in normal culture conditions (in
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the presence of S10 and IL-7) or in cultures to which 14µM antisense oligonucleotides
or varying concentrations of DMSO were added. Protein was isolated from 1x106 pro-B
cells in Laemmli’s buffer and separated on 8% denaturing polyacrylamide gels. Gels
were transferred to PVDF membrane and blocked for 30 minutes in PBS with 5% dry
milk. Blots were than probed with a primary monoclonal mouse C-myb antibody (Clone
1.1, Upstate Biotechnology, 1 µg/ml) or monoclonal mouse GAPDH (glucose-aldehydephosphate dehydrogenase) antibody (Research Diagnostics, 0.5 µg/ml) in PBS with 3%
milk overnight at 4oC. Blots were then washed with one change of water and probed
with a goat α-mouse Ig-HRP as the second antibody for 2 hours at room temperature.
Blots were washed with one quick wash of water, one 15 minute wash of TBS with 0.1%
Tween, and then 5 vigorous washes in water at room temperature for one minute. ECL
plus (Amersham) was used as a chemiluminescent reagent and then blots exposed to
Kodak X-OMAT film. Densitometry analysis was done using Eagle Eye Software.
Cell Depletion. G10 Sephadex was used to deplete adherent stromal cells from pro-B
cell suspensions. Sterile G10 columns were prepared as described by Kincade et al
(1981). Sterile 10 ml syringe barrels were plugged with glass wool, autoclaved, and
filled with 8 mls of sterile pre-swollen G10 Sephadex. Columns were washed with
sterile PBS and equilibrated with 20 mls warm media. Two mls of media containing
5x106 C1.92 cells were applied to each column. Columns were incubated at room temp
for 30 minutes. Cells were then washed from columns with 30 mls of warm media.
DNA Isolation and Ig gene rearrangment status.

DNA was isolated from 1x106

C1.92 cells using the Easy-DNA isolation kit (Invitrogen). DNA was RNAse treated to
remove contaminating RNA and resuspended in 100 ml of Tris-EDTA (pH 8). 500 ngs
of DNA were used in an RT-PCR reaction (Promega) to determine immunoglobulin (Ig)
gene rearrangement status.

The Ig heavy chain is assembled from a variable (V)

region, a diversity (D) region, a joining (J) region, as well as a constant region. These
loci are separated from one another in the germline by intervening sequences and are
joined together upon B cell differentiation. Ig heavy chain gene rearrangement status
was determined using primer sets that are complementary to the intervening sequence
between the V and D section of the heavy chain gene (using primers DFL16.1; 1227 bp
amplicon) and between the D and J section of the heavy chain gene (using primers JH1;
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472 bp amplicon). The sequence of primer sets was as follows: DFL16.1 (sense primer) –
5’-GCCTGGGGAGTCACTCAGCAGC-3’;
(antisense primer) – 5’-GTGTGGAAAGCTGTGTATCCCC-3’ and
JH1 (sense primer) - 5’- CCCGGACAGAGCAGGCAGGTGG-3’ and
(antisense primer) –5’-GGTCCCTGCGCCCCAGACA-3’. Amplification was performed
for 35 cycles with denaturation at 95oC for 1 minute, annealing at 58oC for 3 minutes,
and extension for 4 minutes at 72oC with an additional 15 minute extension added to the
final cycle. Loss of a DFL16.1 or a JH1 amplicon was indicative of gene rearrangement.
DNA from identically prepared S10 was used to confirm germline configuration.
GAPDH ((sense primer)5’-TGAAGGTCGGTGTGAACGGATTTGG-3’ (antisense primer)
5’-ACGACATACTCAGCACCGGCCTCAC-3’)) amplification was used as a control for
template integrity and normalization of data. PCR products were separated on 2%
ethidium bromide stained gels and visualized using Eagle Eye (Stratagene).
Proliferation assay. Following culture with DMSO or oligonucleotides, 1x105 viable
C1.92 cells were allocated in 96 well plates coated with S10 and 200 µl of α-MEM
media. Cells were cultured over night for 18 hours, and then pulsed with 1 µCi 3HTdR/well. After 6 more hours of culture, cells were harvested onto glass wool fiber
strips with an automated cell harvester. Radioactive incorporation was determined by
liquid scintillation counting in an aqueous fluor (Biosafe-II).

Each treatment was

repeated in triplicate.
Cell Cycle Analysis. C1.92 cells were cultured with DMSO or oligonucleotides as
previously described. 1x106 cells were fixed in 70% EtOH (at –20oC) and treated with
20 µg RNase A (Sigma) at 37oC for 30 minutes. Cells were then stained with 50 µg/mL
propidium iodide (PI) (Sigma) to evaluate DNA content. PI stained cells were evaluated
using a flow cytometer (FACScan; Becton Dickinson) and analyzed using ModFit
Software.
Fluorescent Staining. For surface Ig, flt-3, BP-1, HSA (CD24), and CD43 staining, 106
C1.92 cells were harvested after being cultured with PBS, scrambled oligonuclotide, or
antisense olignucleotide for 0 or 60 hours.

Cells were washed with ice-cold PBS

containing 0.1% heat inactivated fetal bovine serum (PBS/FBS). Cells were aspirated to
dryness, resuspended in 25 µl of PBS and stained with 1 µg/ml FITC conjugated
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primary antibody (or a corresponding isotype) for 30 minutes at 4oC. Cells were then
washed twice with PBS/FBS and resuspended in 500 ml of PBS and 500 ml of
paraformaldehyde buffer (2%).

Samples were analyzed using a flow cytometer

(FACScan; Becton Dickinson) and WinMidi software.

RESULTS
Effect of DMSO on C-myb Expression in Pro-B Cells. DMSO treatment (Collins,
1978; Westin, 1982) was utilized to downregulate C-myb levels in pro-B cells while
allowing them to remain in the presence of stromal cells. C1.92 cells were cultured with
several different concentrations of DMSO to determine optimal concentrations for c-myb
downregulation. C1.92 cells were cultured with 0%, 0.5%, 0.75%, 1.0%, 1.25%, and
1.5% DMSO for 2 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, and
144 hours. A dose dependent response to DMSO was observed. C-myb protein levels
were not altered after 24 hours of culture with the lowest concentrations of DMSO.
However, 24 hours of culture with the highest DMSO concentration (1.5%) resulted in
undetectable C-myb protein expression in pro-B cells. In order to avoid any toxicity to
pro-B cell cultures, C1.92 cells were treated with moderate levels of DMSO and
evaluated at 48, 72, and 96 hours post treatment. After 72 hours of culture, C.192
treated with 0.5% DMSO had a 15% reduction in C-myb protein while pro-B cells
treated with 1.0% DMSO had a 50% reduction in C-myb expression. Within 96 hours Cmyb protein expression was almost undetectable in cultures treated with 1.0% DMSO,
but was still present in pro-B cells cultured with 0.5% DMSO (figure 1).
DMSO Treatment Does Not Decrease Cell Viability. After treatment with DMSO, cell
viabilities were assessed using trypan blue exclusion. C1.92 cells were cultured with
moderate concentrations of DMSO, 0.5% and 1.0% DMSO, for 48, 72, and 96 hours.
As discussed above, there was a decrease in C-myb protein in C1.92 cells treated with
1.0% DMSO within 72 hours and levels were almost undetectable by 96 hours.
However, there was no change in viabilities of treated or untreated pro-B cells (figure 2).
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Figure 1. Effect of DMSO on C-myb Expression in Pro-B Cells.

C1.92 cells were

treated with culture medium alone, medium containing 0.5% DMSO, or medium
containing 1.0% DMSO for 48, 72, or 96 hours. 106 live C1.92 cells were harvested and
C-myb protein levels were determined by Western Blot analysis. Data is shown as Cmyb protein density as a percentage of untreated controls. Data is representative of 3
replicate experiments.
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Figure 2. DMSO Treatment Does Not Decrease Cell Viability. C1.92 cells were
treated with culture medium alone, medium containing 0.5% DMSO, or medium
containing 1.0% DMSO for 48, 72, or 96 hours. Cell viability of both treatment groups
was then determined using trypan blue exclusion. Data presented is one of 3 replicate
experiments.
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Non-Specific Inhibition of C-myb Results in Decreased Pr-B Cell Expansion in
Culture. After treatment with DMSO, C1.92 cells were enumerated to assess total
number of cells in culture.

C1.92 cells left untreated or treated with 0.5% DMSO

expanded in culture over the experimental timecourse. However, as shown in figure 3,
C1.92 cells with downregulated C-myb expression (by treatment with 1.0% DMSO)
expanded less in culture.
Downregulation of C-myb is Associated with Ig Gene Rearrangement.

C-myb

downregulation has been associated with the maturation and differentiation of myeloid
cells. In order to determine if C-myb was involved with progression through the B
lineage pathway, gene rearrangement status of the Ig heavy chain gene in C1.92 cells
was evaluated. Prior to any treatment regime, C1.92 cells have both the D-J and V-DJ
segments of the Ig heavy chain gene in germline configuration (figure 4, 0 hour), and
they remain germline throughout the entire culture period. C1.92 cells were cultured
with 1.25% DMSO for 24 or 48 hours. After treatment, C1.92 cells were removed from
culture and depleted of any adherent stromal cell contamination. This was to ensure
that S10 DNA, which is in germline configuration, would not contaminate C1.92 DNA.
After culture for 24 hours, pro-B cells cultured with 1.25% DMSO rearranged genes at
the D-J loci. Within 48 hours, genes at both the D-J and V-DJ loci were rearranged
(figure 4, 1.25% DMSO). Gene rearrangement also occurred in C1.92 cells treated with
1.0% DMSO, however 144 hours of culture with DMSO was necessary to induce gene
rearrangement.

In untreated control cultures, gene rearrangement was not observed.

As a control, GAPDH expression was evaluated.
treatment groups.

GAPDH was unchanged in all

This indicates that genotypic maturation occurs after C-myb

downregulation in pro-B cells.
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Figure 3. Inhibition of C-myb Results in Decreased Pro-B Cell Expansion in
Culture. C1.92 cells were cultured for 48, 72, or 96 hours in tissue culture media alone,
in media containing 0.5% DMSO, or in media containing 1.0% DMSO. Cell recovery
and cell viability were determined.

Data shown is mean and SEM of 3 replicate

experiments.
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Figure 4. Downregulation of C-myb is Associated with Pro-B Cell Differentiation.
C1.92 cells were treated with cell culture medium alone or medium containing 1.25%
DMSO for 24 or 48 hours.

DNA was isolated from 106 pro-B cells.

RT-PCR

amplification was performed using primers designed to detect gene rearrangement, as
well as GAPDH primers to check template integrity.
experiments is shown.
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Data from one of 3 replicate

C1.92 Pro-B Cell

S10 Stromal Cell

1.5% DMSO treated
S10 Stromal Cell
76 kDa

Figure 5. Stromal Cell C-myb Levels Are Not Altered By DMSO Treatment. Nonconfluent flasks of S10 stromal cells were treated with 1.5% DMSO for 48 hours. After
48 hours of DMSO treatment, C-myb protein expression was examined by western blot
analysis. Data from one of 3 experiments is presented.
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C-myb Downregulation Results in Cell Surface Expression of Immunoglobulin but
Not in Other Phenotypic Changes.

In addition to genotypic alterations, B cell

maturation is accompanied by several phenotypic alterations. After immunoglobulin
heavy chain gene rearrangement, surface Ig expression is an indicator of progression
through the B lineage pathway. Under normal culture conditions, C1.92 cells do not
express cell surface immunoglobulin; C1.92 cells are CD43hi, CD24lo, CD45Rlo, flt-3lo,
and sIg-. C1.92 cells treated with 0.5% DMSO remained sIg-. However, pro-B cells
treated with 1.0% DMSO that exhibited downregulation of C-myb had an increase in the
expression of surface immunoglobulin (sIg) as detected by fluorescent staining.

In

addition to surface Ig expression, alterations in several other cell surface molecules
have been correlated with stages in B cell development.

These changes include

increased expression of flt-3, CD24 (Heat Stable Antigen), BP-1, and CD45R.

C1.92

cells treated with 0.5% and 1.0% DMSO exhibited no alterations in these cell surface
molecules. No changes in BP-1, CD24, CD45R, or flt-3 were observed after 96 hours of
treatment with 1.0%.

These data indicate that downregulation of C-myb results in

rearrangement of immunoglobulin heavy chain genes, expression of immunoglobulin on
the cell surface, and pro-B cell maturation, but not in changes of other cell surface
molecules.
Stromal Cell Alterations Following DMSO Treatment.

Several changes were

observed in C1.92 cells after treatment with DMSO. However, since they are grown in
co-culture with stromal cells, it was necessary to ensure that DMSO was not also
affecting stromal cell characteristics. Therefore S10 stromal cells were also treated with
media containing 1.5% DMSO, the highest concentration used for any of these
experiments, for 48 hours. S10 stromal cells do not normally express C-myb mRNA or
protein. Culture with DMSO for 48 hours did not induce C-myb expression (figure 5). In
addition, the cytokine profile of S10 stromal cells was examined after culture with 1.5%
DMSO for 48 hours. RT-PCR showed little to no changes in stromal cell expression
levels of IGF-1 or IL-7 (figures 6 and 7). Although there appears to be a slight increase
in IL-7 mRNA following DMSO treatment, a proliferation assay showed no increase in
functional IL-7 protein. PCR of DNA from DMSO treated stromal cells revealed that the
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Ig genes of stromal cells remained in germline configuration (figure 8). These data
indicate that DMSO treatment alters c-myb expression and Ig gene rearrangement
status in pro-B cells but not in stromal cells. And, stromal cells treated with DMSO
neither have alterations of B cell specific cytokines (IL-7 and IGF-1) nor do they exhibit
an impaired ability to support pro-B cells in culture. Therefore, the effects of DMSO in
the pro-B cell/stromal cell culture are specific to B cell progenitors.
Regulation of C-myb Expression in Pro-B Cells Using Antisense
Oligonucleotides. Although DMSO treatment was effective at downregulating C-myb
in pro-B cells, the mechanism by which this is accomplished is non-specific. In order to
specifically downregulate C-myb expression in pro-B cells, antisense oligonucleotides
were utilized. Antisense oligonucleotides were cultured with pro-B cells for 60 hours.
As controls, pro-B cells were also cultured with a scrambled sequence of
oligonucleotides. The scrambled oligos had the same G/C and A/T content as did
antisense oligos, however the nucleotides were in random order. This was used to
ensure that any effects observed were due to specificity of antisense oligonucleotides
and not due to non-specific oligonucleotide effects. In addition, cultures were also
treated with PBS since this served as the solvent for reconstituting antisense and
scrambled designed complimentary to the start site of the c-myb mRNA. Pro-B cells
were cultured with stromal cells and 14 µm oligos. After 60 hours of treatment C-myb
protein was significantly decreased in cultures treated with antisense oligonucleotides
but was unchanged in scrambled or PBS treated cultures (figure 9).
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Figure 6. DMSO Treatment of Stromal Cells Does Not Alter IGF-I Expression. S10
stromal cells were treated with DMSO for 48 hours. RNA was isolated from treated
cells and RT-PCR was performed. GAPDH was amplified as an internal control. Data
from one of three experiments is shown.
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Figure 7. DMSO Treatment of Stromal Cells Does Not Alter IL-7 Expression. S10
stromal cells were treated with DMSO for 48 hours. RNA was isolated from treated
cells and RT-PCR was performed. GAPDH was also amplified as an internal control.
Data from one of three experiments is pictured.
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Figure 8. Stromal Cell Ig Gene Rearrangement Status is Not Altered by DMSO
Treatment. Non-confluent flasks of S10 stromal cells were treated with 1.5% DMSO for
48 hours. After 48 hours of DMSO treatment, DNA was isolated from stromal cells and
PCR amplified to detect gene rearrangement status.
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Regulation of C-myb Expression in Pro-B Cells Using Antisense

Oligonucleotides. C1.92 cells were grown in medium with S10 and IL-7 for 24 hours.
14µM c-myb scrambled oligonucleotides, 14µM c-myb antisense oligonucleotides, or
saline solvent were then added to the culture for 60 hours. After 60 hours, 106 live cells
were collected and C-myb protein analyzed by Western Blot. Data shown is one of 5
representative experiments.
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Antisense Oligonucleotide Treatment Does Not Decrease Cell Viability.

As with

DMSO, the viability of C1.92 cells after treatment with oligonucleotides was examined
using trypan blue exclusion.

Downregulation of C-myb by culture with antisense

oligonucleotides resulted in no changes in cell survival.

These data indicated that pro-

B cell survival was not altered by specific decreases in C-myb expression (figure 10).
Specific Inhibition of C-myb Results Decreased Pro-B Cell Expansion in Culture.
After treatment with oligonucleotides, C1.92 cells were enumerated to
assess total number of cells in culture. C1.92 cells treated with PBS or treated with
scrambled oligonucleotides expanded in culture over the experimental timecourse.
However, as shown in figure 11, C1.92 cells with downregulated C-myb expression (by
treatment with antisense oligonucleotides) expanded less in culture.
Inhibition of C-myb Results in a Decreased Response to IL-7.

Since C-myb

downregulation by antisense oligonucleotides inhibited pro-B cell expansion, the ability
of C1.92 cells to respond IL-7, their major proliferative stimulus, was evaluated. C1.92
cells were treated either with PBS, scrambled oligonucleotides, or antisense
oligonucleotides for 60 hours. After 60 hours of treatment cells were washed and plated
in S10 coated-96 well plates, with or without IL-7 as indicated in figure 12. Pro-B cells
treated with PBS or scrambled oligonucleotides proliferated in response to IL-7
exposure.

However, pro-B cells treated with antisense oligonucleotides nucleotides

exhibited a decreased proliferative response following IL-7 exposure (figure 12,
antisense).
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Antisense Oligonucleotide Treatment Does Not Decrease Cell

Viability. C1.92 cells were cultured for 60 hours in media alone or in media containing
PBS, 14 µM c-myb scrambled oligonucleotides, or 14 µM c-myb antisense
oligonucleotides. Cell viability of both treatment groups was then determined using
trypan blue exclusion. Data shown is representative of 5 experiments.
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Figure 11. Inhibition of C-myb Results in Decreased Pro-B Cell Expression in
Culture. C1.92 cells were cultured for 60 hours in tissue culture medium alone or in
medium containing PBS, 14µM c-myb scrambled oligonucleotides, or 14 µM c-myb
antisense oligonucleotides. Cell recovery and cell viability was determined. Data is
presented as one of 5 experiments.
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Figure 12. Inhibition of C-myb Results in a Decreased Response to IL-7. C1.92
cells were cultured for 60 hours in tissue culture medium containing PBS, 14µM c-myb
scrambled oligonucleotides, or 14 µM c-myb antisense oligonucleotides. Cell recovery
and cell viability was determined. After treatment, 105 C1.92 cells were cultured on S10
with or without IL-7 for 18 hours in 96 well plates. Cells were pulsed with tritiated
thymidine following an 18 hour exposure to IL-7. Data is presented as mean and SEM
of 3 replicate wells. Experiments were conducted a minimum of 3 times.
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DISCUSSION
Although c-myb has been shown to be critical in the development of erythroid
and myeloid precursors, less work has been done on the role of c-myb in the normal
development of lymphocytes.

Because c-myb deletion in vivo results in embryonic

lethality, it is difficult to investigate c-myb regulation in developing B lymphocytes. Much
of the erythroid and myeloid work has been accomplished using an in vitro cell model.
Therefore, an appropriate model of B cell development must be utilized to determine the
role of c-myb in B lymphopoiesis. The aim of this work was to develop a system in
which c-myb expression in pro-B cells could be downregulated while they remain in coculture with stromal cells. In addition, this work will determine whether c-myb is an
intracellular regulator of survival, proliferation, and/or differentiation in early B cell
progenitors.

This project demonstrates that the addition of DMSO or antisense

oligonucleotides to pro-B cell cultures results in c-myb downregulation, even in the
presence of stromal cells. These data also clearly establish the role of c-myb in the
proliferation and differentiation of stromal-cell dependent pro-B cells.
Expression and regulation of the proto-oncogene c-myb are critical events in the
maturation of myeloid lineage cells. Myeloid differentiation has primarily been studied
using tumor cell models comprised of cells blocked in a specific hematopoietic
differentiation state. The HL-60 tumor cell line has been an in vitro model widely utilized
to dissect the processes involved in myeloid cell development. HL-60 cells are a human
leukemic cell line established from the peripheral blood leukocytes of a patient with
acute promyelocytic leukemia. HL-60 cells are primarily promyelocytes arrested in an
immature proliferative state. Previous data from Collins et al had demonstrated that
addition of DMSO to HL-60 cell cultures would induce terminal differentiation of the promyelocytes into mature neutrophils and monocytes (Collins, 1977). The mechanism
responsible for inducing maturation was unknown.

In 1982, Westin et al further

investigated the differentiation of HL-60 cells and discovered that the maturation of promyelocytes correlated with a significant decline in c-myb expression. This finding laid
the foundation to further expand the role of c-myb in myeloid cell development.
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In 1988, Clark et al demonstrated that constitutive expression of exogenously
introduced c-myb inhibited erythroid differentiation in a murine erythroleukemia cell line
(Clark, 1988). McClinton and collaborators further expanded Clarke’s findings. They
investigated the effects of ectopic C-myb over expression at different times during
differentiation using a Friend virus-infected MEL cell line. The MEL cell line is an early
erythroid precursor model that can be induced to differentiate into mature erythroid cells
using chemical inducers, including erythropoietin and DMSO. During early and late
stages of MEL cell differentiation, c-myb mRNA is biphasically downregulated.
(Kirsch,1986 and Ramsay, 1986).

McClinton et al introduced an inducible

metallothionein promoter driven c-myb gene into MEL cells and expressed c-myb during
different phases of differentiation. Expression of c-myb during the early phase of
differentiation did not have an affect on MEL cell maturation, indicating that early downregulation of c-myb is not necessary for differentiation.

However, if c-myb was

continuously expressed during the entire induction phase, differentiation was completely
blocked indicating that late down-regulation of c-myb is critical for terminal differentiation
of MEL cells (McClinton, 1990). Recently, in 2001, Chen and Bender demonstrated that
MEL cells could be induced to differentiate into a more mature cell by introducing an
inducible dominant interfering myb allele (MEnT). Introduction of MEnT in MEL cells
resulted in the cessation of proliferation and initiation of differentiation without chemical
induction. These experiments demonstrate that c-myb downregulation alone (in MEL
cells) is sufficient to induce terminal differentiation (Chen and Bender, 2001). Taken
together these data supported a critical role for c-myb in myeloid and erythroid
hematopoiesis: down regulation of c-myb is required for terminal differentiation of
myeloid and erythroid cells.
We previously developed a cloned fetal liver pro-B cell line that is dependent on
stromal cells and IL-7 for continued survival and proliferation (Gibson, 1996).

This

cloned pro-B cell line, termed C1.92, remains dependent on the presence of stromal
cells for survival and proliferation, does not form tumors, and reconstitutes B
lymphocytes in severe combined immunodeficient (SCID) mice. However, studies of
the pro-B cell clone show it is characterized by rapid and continuous proliferation. We
noted this continuously growing pro-B cell line was characterized by unusually high
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levels of c-myb expression. Culture of C1.92 pro-B cells without stromal cells resulted
in decreased c-myb expression. However, C1.92 cells are dependent on stromal cell
adhesion contacts for survival signals. Due to decreased cell viability, culture without
stromal cells is not the best way to investigate the role of c-myb in B cell development.
Previous work by Westin indicated that c-myb in myeloid cells could be non-specifically
downregulated after culture with DMSO. Although the mechanism by which DMSO
decreases c-myb expression is not known, it is nevertheless an effective method to alter
c-myb levels. To determine if this would work with pro-B cells, C1.92 cells were cocultured with S10 stromal cells and exogenously added IL-7. DMSO was then added to
pro-B cell cultures at varying concentrations. C1.92 cells exhibited a dose-response
decrease in C-myb expression after treatment with DMSO. C-myb protein expression
was only slightly altered after 48 hours of culture with 0.5% DMSO but was
undetectable in pro-B cells cultured with 1.25% or 1.5% DMSO. This approach allowed
us to downregulate C-myb expression in pro-B cells while allowing them to remain in coculture with stromal cells. However, since this is a co-culture system, it was necessary
to ensure that DMSO treatment was not altering stromal cells. S10 stromal cells do not
express mRNA or protein for c-myb and they retain Ig heavy chain genes in germline
configuration. After treatment with 1.5% DMSO for 48 hours, S10 stromal cells still do
not express c-myb mRNA or protein and their Ig heavy chain genes remain in germline
configuration.

In addition, the cytokine profile of stromal cells was examined after

DMSO treatment. It has been previously reported in the literature that DMSO treatment
causes alterations of IL-6 message.

It was necessary to determine if DMSO was

altering other cytokines produced by stromal cells that may influence B cell
development. In particular, IGF-1 and IL-7 messages were examined because of their
importance in pro-B cell proliferation and differentiation. Again, S10 stromal cells were
treated with 1.5% DMSO for 48 hours, and IGF-1 and IL-7 message were amplified by
RT-PCR.

No significant differences in IGF-1 or IL-7 mRNA levels were seen in

untreated S10 stromal cells compared with those treated with DMSO.

In addition,

stromal cells treated with DMSO were still able to support pro-B cell cultures. Pretreatment of S10 with DMSO did not alter the cell viability or c-myb levels of pro-B cells
in the co-culture. Therefore, DMSO treatment of pro-B cell/stromal cell cultures resulted

105

in significant decreases in C-myb expression in pro-B cells but did not result in
significant alterations of the stromal cell feeder layer.
Although DMSO treatment was found to be an effective method to downregulate
c-myb expression, it suffers because it is non-specific. In 1988, Gewirtz and Calabretta
first reported the use of c-myb antisense oligonucleotides to specifically downregulate cmyb expression (Gewirtz and Calabretta, 1988).

In the current work, antisense

oligonucleotides complimentary to the start site of the c-myb mRNA were used.
Antisense oligo were added to cultures of pro-B cells and stromal cells at 14 µm for 60
hours. After 60 hours of treatment, there was a significant decrease in C-myb protein
as determined by Western Blot. Therefore, a model system has been developed in
which C-myb expression in IL-7, stromal cell dependent pro-B cells can be
downregulated both specifically by antisense oligonucleotides and non-specifically by
DMSO addition. This in vitro system allows us to examine the importance of c-myb in B
lymphoid development.
We determined

whether

c-myb

regulated

differentiation of developing B lineage cells.

survival,

proliferation,

and/or

When c-myb was downregulated by

moderate doses of DMSO (1.0%) or by antisense oligonucleotides, there was no
change in viability of treated cells. C-myb remained at undetectable levels in pro-B
cells, yet they continued to survive. These data suggested that pro-B cell survival is cmyb independent.
Although the pro-B cells continued to survive while c-myb was downregulated,
we observed a marked impairment in the ability of pro-B cells to expand in culture.
Enumerating total cells in culture after treatment with DMSO revealed that there were
25% fewer cells in the cultures containing 1.0% DMSO than were present in untreated
cultures. In cultures treated with antisense oligonucleotides, there was a 50% reduction
in the number of cells recovered after 60 hours of treatment. Since cell viabilities were
not decreased, the decreased number of cells in culture was not due to cell death. For
that reason, the proliferative potential of pro-B cells with decreased c-myb levels was
evaluated. Pro-B cells proliferate in response to the stromal cell derived cytokine IL-7.
C1.92 cells were cultured with stromal cells, exogenous IL-7, and tritiated thymidine for
24 hours. Thymidine uptake was used as an indicator of the proliferative potential of
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C1.92 cells. C1.92 cells with decreased c-myb levels displayed an inability to proliferate
in response to stromal cells and IL-7. Therefore, pro-B cells with downregulated c-myb
failed to expand in culture and were unable to proliferate in response to IL-7. This
indicates that c-myb expression in pro-B cells is necessary for maintenance of the
progenitor cell population.
The B cell progenitor stage is the main proliferative compartment of developing
B lineage cells.

As pro-B cells mature into pre-B cells, they loose some of their

proliferative ability. Since pro-B cells with decreased C-myb levels had a decreased
proliferation rate, but continued to survive in culture, we wanted to determine if C1.92
cells differentiated into pre-B cells. Ig gene rearrangement gene status of C1.92 cells
was evaluated. C1.92 cells are early pro-B cells that retain both the D-J and the V-DJ
loci of their Ig heavy chain gene in germline configuration. Maturation into late pro-B
cells or early pre-B cells would be indicated by rearrangement of the D-J and V-DJ loci.
This can be detected using PCR primers complimentary to the intervening regions
between the V, D, and J segments. If Ig genes are unrearranged, the intervening
sequences between the V, D, and J will be amplifiable by PCR.

However, once

rearrangement occurs, the intervening sequences are excised out and will no longer be
detectable by PCR. C1.92 cells were treated with 1.25% DMSO for 24 or 48 hours.
1.25% DMSO was used because treatment with this concentration resulted in
undetectable C-myb protein within 48 hours. 24 hours after culture with DMSO, C1.92
pro-B cells had rearranged the D-J segment of the Ig heavy chain gene; within 48 hours
V-DJ rearrangement had occurred. These data indicate that downregulation of C-myb
is necessary for pro-B cell genotypic differentiation. However, there are also phenotypic
changes that correlate with B cell maturation stages. Loss of CD43 and an increase in
flt-3, BP-1, HSA, and sIg are indicative of B cell maturation. However, C1.92 cells
treated with DMSO or antisense oligonucleotides did not exhibit any change in these
markers. Therefore, although genotypic maturation is regulated by C-myb expression,
phenotypic maturation is C-myb independent. Genotypic maturation usually correlates
with phenotypic changes. However, these data indicate that genotypic and phenotypic
maturation are correlative, not causative, and that C-myb regulates one aspect of
maturation but not the other.
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Taken together, these data establish c-myb as an intracellular regulator of
proliferation and genotypic differentiation in IL-7, stromal cell dependent pro-B cells but
not as a regulator of survival. As early immature cells, pro-B cells require contact with
stromal cells for their continued survival, proliferation, and differentiation. These data
suggest that pro-B cells receive survival signals directly from stromal cells. However,
the proliferation and differentiation of pro-B cells are regulated through stromal cell
control of the proto-oncogene c-myb. We previously demonstrated that stromal cell
contact maintains a high level of c-myb expression in pro-B cells. As pro-B cells mature
into pre-B cells, they lose their dependence on stromal cells. So, as pro-B cells detach
from stromal cells, there is a decrease in c-myb expression. This decrease in c-myb
expression causes a decreased responsiveness to IL-7 and cessation of proliferation.
Following a decrease in proliferative potential, genotypic maturation of pro-B cells into
pre-B cells occurs.

Therefore, stromal cells coordinate progression through the B

lineage pathway by regulating c-myb expression.
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Chapter 4

Loss of A-myb and C-myb Differentially Impact B Lymphopoiesis in
Murine Fetal Liver
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ABSTRACT
The differentiation of hematopoietic stem cells into B lymphocytes occurs in a
hierarchal fashion during which stem cells develop first into lineage committed
progenitor cells and then into precursor cells having decreased proliferative potential
and increased lineage commitment. To dissect the molecular events regulating this
process, in vivo deletion of specific genes can be utilized. This technique has been
used to delete many target genes, including the DNA binding proteins a- and c-myb. In
vivo deletion of c-myb results in embryonic lethality due to a complete failure of fetal
liver erythropoiesis.

Embryonic

inactivation

of

the

a-myb

gene

results

in

spermatogenesis and breast development defects. However, the effect of embryonic
myb deletion on B lymphopoiesis has not been described. To better understand the
biological function of a- and c-myb in B lymphopoiesis, we have utilized the available
myb knockout mice. Homozygous c-myb mutant mice display complete failure of B
lymphopoiesis in the fetal liver of day 13.5 mice. However, homozygous a-myb mutant
mice appear to have no defects in B lymphopoiesis.

These results suggest that

embryonic expression of c-myb is critical for embryonic B cell development while a-myb
expression is not required.
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INTRODUCTION
The c-myb proto-oncogene, the cellular homolog of the v-myb gene, is expressed
in highly proliferative, immature progenitor cells of the myeloid, erythroid, and lymphoid
lineages (Klempnauer,1982). Transcription levels of c-myb are dramatically reduced as
progenitor cells differentiate into more mature cells (Westin et al, 1982, Gonda and
Metcalf 1984). C-myb expression is found in embryonic stem cells and neural tissues of
embryonic, fetal, and adult brain (Dyson 1989, Thiele 1988).

Fibroblasts and T

lymphocytes express c-myb transiently during cellular proliferation (Stern and Smith,
1986, Thompson, 1986, Lipsick and Boyle, 1987). Over-expression of c-myb has been
associated with leukemias and neoplasms. Human neuroectodermal and hematopoietic
malignancies, as well as carcinomas of lung, colon, and breast, have all been reported
to express c-myb (Alitalo, 1984; Griffin and Baylin, 1985; Thiele, 1987; Salmon 1984;
Slamon 1986; Torelli, 1987). The expression pattern of the c-myb gene suggested a
role for c-myb in hematopoiesis and developmental processes. The development of a
mouse model with a homozygous mutant c-myb gene confirmed these data (Mucenski,
1991).
To better define the normal biological function of c-myb, Mucenski et al
generated a mouse model heterozygous for a mutated c-myb gene. Mice heterozygous
for mutant c-myb appeared phenotypically normal after birth. However, no c-myb null
animals were present postnatally, suggesting that the c-myb mutation was lethal. In
utero examinations of animals, at day 13 of gestation, revealed that homozygous null
embryos were indistinguishable from c-myb wildtype embryos. They were present in
appropriate numbers and had developed brains, kidneys, lungs, hearts, and limb buds.
However, by day 15, mutant mice were pale in color, severely anemic, and expired in
utero. At days 12.5-13.5 of gestation, hematocrit levels in wild type and mutant mice
were 35%. By day 15.5, there was a 10-fold decrease in hematocrits of c-myb null
mice. Null mice had hematocrit levels of 5% whereas wild-type animals had 40%.

At

this time in embryogenesis, the site of erythropoiesis moves from the AGM region into
the fetal liver. Erythrocytes derived from the AGM can be morphologically differentiated
from fetal liver derived erythrocytes; erythrocytes from the AGM region remain
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nucleated and are larger than those from the fetal liver. Examination of peripheral blood
at day 12 revealed normal numbers of nucleated erythrocytes, indicating that early
intraembryonic erythropoiesis in the AGM was normal. However, there was a significant
defect in fetal hepatic erythropoiesis.

Animals exhibited a complete loss of

erythropoiesis in the fetal liver. This indicates that c-myb mutant mice are unable to
switch the site of fetal erythropoiesis from the AGM region to the liver (Mucenski, 1991).
These observations clearly establish that c-myb is responsible for the maintenance of
myelo and erythropoiesis.

Although c-myb has been shown to be critical in the

development of erythroid and myeloid precursors, less work has been done on the role
of c-myb in the normal development of lymphocytes.
C-myb is closely related to another member of the Myb gene family, a-myb.
Unlike c-myb, a-myb is expressed in a tissue-specific fashion. The A-myb protein is
primarily found in breast epithelial cells of pregnant mice and in male germ cells. A-myb
has also been detected in ovaries, brain, and germinal center B cells (Mettus et al,
1994, Trauth et al, 1994). DeRocco et al showed in 1997 that mice over expressing the
A-myb protein develop hyperplasia of the spleen and lymph nodes.

These mice

exhibited increased DNA synthesis and a polyclonally expanded B cell population
(DeRocco et al, 1997). Development of a homozygous null mutant mouse deficient in
A-myb protein further clarified the role of a-myb. Mice homozygous for a germline
mutation in the a-myb gene are present postnatally and appear normal at birth.
However, during the first weeks of life, the pups lagged behind in growth appearing
small, wrinkled, and hunched. At 4 months of life, however, the mutant pups were
identical to normal littermates in body size. Male mice with a-myb gene mice were
sterile due to a block in spermatogenesis. Female a-myb mutant mice were not sterile
and delivered offspring sired by wild-type or heterozygous males. However, pups born
to a-myb null mothers failed to thrive because the mutant mother mice exhibit abnormal
mammary function and are unable to nurse pups. Taken together, these data suggest
that a-myb may serve as a mediator of proliferation in certain cell types, particularly in
spermatocytes and mammary epithelial cells (Toscani et al, 1997).
Although the literature describes anatomic defects associated with myb mutant
mice, B lymphopoiesis in these animals has not yet been described. This work utilizes
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the currently available myb knockout models to explore B lymphocyte development.
This work demonstrates that loss of c-myb completely ablates B lymphopoiesis while
loss of a-myb does not impact B lymphoid development. C-myb is critical for fetal
development of B cells whereas a-myb is dispensable.

METHODS AND MATERIALS
Mice.

C-myb mutant mice were obtained from Dr. Michael Mucenski at Children’s

Hospital Research Foundation in Cincinnati, OH. Generation of c-myb mutant mice has
been described in detail (Mucenski et al, 1991). Briefly, a vector was constructed with a
neomycin resistance gene inserted in opposite transcriptional orientation into the sixth
c-myb exon. The construct was introduced, by electroporation, into stem cells and cells
containing the construct were identified by G418 selection. Embryonic stem cells with
the construct were implanted into pseudopregnant female mice. The altered c-myb
allele was passed to progeny animals and the affect of the alteration was examined. Cmyb mice were housed in the West Virginia Office for Laboratory Animal Resources.
A-myb mutant mice were obtained from Dr. Premkumar Reddy at Fels Institute
for Cancer Research and Molecular Biology, Temple University, Philadelphia PA.
Generation of a-myb mutant mice has been described in detail (Toscani et al, 1997).
Briefly, a targeting vector was designed in which the neomycin resistance gene was
inserted into exon 4 of the a-myb gene. The vector was electroporated into ES cells.
Cells containing the disrupted a-myb gene were selected by G418 and verified by
Southern Blot analysis. Clones bearing a disrupted a-myb gene were used to generate
a-myb-/- mice. A-myb mice were housed at the West Virginia University vivarium.
Fetal liver preparation.

Day 13.5 fetal livers were removed from wild type,

heterozygous mutant, or homozygous null mice.

They were made into single cell

suspensions after several passages through a 23-gauge needle. White blood cells
were then enumerated and underlayed with 1.5ml fetal bovine serum to remove any
remaining tissues from suspension. Cells were collected in a new tube and enumerated
a second time.
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Colony-forming assays. Recombinant interleukin-7 (rIL-7) -induced colony formation
was measured using culture of fetal liver cell suspensions in methylcellulose.
Methylcellulose, with no additives, was diluted 1:1 using 1x Iscoves medium containing
30% fetal calf serum, 2% l-glutamine, 2% penicillin/streptomycin, and 0.2% 2mercaptoethanol. Triplicate 1 ml cultures were prepared in 35 mm culture dishes with
2.5 x 105 fetal liver cells per culture and 50 U/ml rIL-7. Control cultures with rIL-7 were
also examined. GM-CSF (granulocyte macrophage colony stimulating factor) induced
colony formation was also measured in methylcellulose, prepared as described above.
Triplicate 1 ml cultures were prepared in 35 mm culture dishes with 1 x 105 fetal liver
cells per culture and 50 U/ml GM-CSF. Both CFU-IL-7 and CFU-GM-CSF colonies
were counted using a dissecting microscope after 7 days incubation at 37oC in 5% CO2.
Colonies from CFU-IL-7 and CFU-GM were isolated and cytospin slide preparations
were made.

Slides were stained with Jenner-Giemsa stain and morphology was

examined to ensure that colonies were pure.
Gender determination.

Chromosomal DNA was isolated from embryos using the

Easy-DNA isolation kit (Invitrogen). DNA was RNase treated to remove contaminating
RNA and resuspended in 100 ml of Tris-EDTA (pH 8). The DNA sequence of the Sry
gene, which is Y chomosome specific in the mouse, was amplified using PCR. The
primers

used

for

PCR

were

5’-AAGCGCCCCATGAATGCATT-3’

and

5’-

TCCCAGCTGCTTGCTGATCT-3’ and the expected size of the amplified fragment was
105 nucleotides (Han et al, 1993).
Pro-B cell assay. S10 stromal cells were split into 96 well plates in 50 ml α-MEM
media the day prior to the experiment. On the day of the experiment, fetal liver cells
were seeded onto stromal cell layers at 50, 100, or 200 cells per well with 50 U/ml of rIL-7 and 125 ml α-MEM media. IL-7 was added to pro-B cell cultures after 2 days of
culture. Pro-B cell cultures were incubated at 37oC in 5% CO2 for 5 days.

At 5 days,

wells were examined and those with expanded pro-B cell colonies were counted as
positive.
Proliferation assay. 2.5 x 105 fetal liver cells were allocated in 96 well plates coated
with S10 and 200 µl of α-MEM media. Where indicated, IL-7 (50 U/ml) was added to
the cultures. Cells were cultured over night for 18 hours, and then pulsed with 1 µCi 3H117

TdR/well. After 6 more hours of culture, cells were harvested onto glass wool fiber
strips with an automated cell harvester (Cambridge Instruments, Boston, MA).
Radioactive incorporation was determined by liquid scintillation counting in an aqueous
fluor (Biosafe-II; Research Products International). Each treatment was repeated in
triplicate.
Genotyping of animals. To identify wild-type, heterozygous, and homozygous mutant
c-myb mice, PCR was utilized. Chromosomal DNA was isolated from embryos or tail
clippings using the Easy-DNA isolation kit (Invitrogen). DNA was RNase treated to
remove contaminating RNA and resuspended in 100 ml of Tris-EDTA (pH 8). PCR was
performed with primers complimentary to sequences in c-myb exon 6 that flanked the
inserted neomycin resistance gene. C-myb primer sequences were as follows: (sense)
5’-GCAAGGTGGAACAGGAAGGCTACC-3’

and

(antisense)

5’-

GTGCTTCGGCGATGTGGTAATAGG-3’ (Biosource International, CA). Primers were diluted

from lyophilized solution to 1µg/µl in autoclaved water.
were used.

PCR mixtures were:

Reaction mixtures of 25 µl

25 µl Stratagene Optiprime Buffer #8, 5 µl 60%

sucrose, 1 µl 10 mM (each) dNTP, 0.5 µl Stratagene Master Mix, 0.2 µl c-myb sense
primer, 0.2 µl c-myb antisense primer, 1.0 µl 25mM MgCl2, 0.5 µl Promega Taq, 250 ng
genomic DNA, and water to 25 µl. Initially, the reaction mixture was activated with a hot
start for 2 minutes at 95oC.

Then, amplification was performed for 35 cycles with

denaturation at 95oC for 30 seconds, annealing at 65oC for 30 seconds, and extension
for 2 minutes at 72oC with an additional 10 minute extension added to the final cycle.
PCR amplifications were performed in a GeneAmp PCR System 9700 (Perkin Elmer
Applied BioSystems). PCR products were resolved on a 2% agarose gel to identify
amplified bands. Expected band sizes were 200 bp (wild-type c-myb gene) or 1548 bp
(mutated c-myb gene).
To identify wild-type, heterozygous, and homozygous mutant a-myb mice, PCR
was also utilized. 2 sets of PCR primers were utilized to genotype a-myb animals. Amyb PCR primers were complimentary to sequences in a-myb exon 4 and they flanked
the inserted neomycin resistance gene. In addition, neo primers were used that were
complimentary to the inserted neomycin resistance cassette. A-myb and Neo primers
were obtained from Biosource International and diluted to 1 µg/µl in autoclaved water.
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A-myb primer sequences were (sense) 5’-GTATACTTAAATTTGGGCTAATTT-3’ and
(antisense) 5’-TAAATTTTTTCAAAAGAATATGAA-3’. Amplification was performed for
35 cycles with denaturation at 94oC for 1 minute, annealing at 55oC for 2 minutes, and
extension for 3 minutes at 72oC with an additional 15 minute extension added to the
final cycle in a Perkin Elmer 480 DNA Cycler. The a-myb PCR reaction included 4 µl
Promega MgCl2, 5 µl 10 x Promega Buffer, 5 µl dNTP, 1 µl sense a-myb primer, 1 µl
antisense a-myb primer, 1 µl Promega Taq, 250 ng DNA, and autoclaved water to 50 µl.
The expected a-myb amplicon size was 200 bp (a-myb wildtype).
Neo primer sequences were:
(sense)

5’-GATGGATTGCACGCAGGTTCTCCGG-3’

ATGGGCAGGTAGCCGGATCAAGCGT –3’.

and

(antisense)

5’-

The neo PCR reaction included 4 µl

Promega MgCl2, 5 µl 10 x Promega Buffer, 5 µl dNTP, 1 µl sense neo primer, 1 µl
antisense neo primer, 1 µl Promega Taq, 250 ng DNA, and autoclaved water to 50 µl.
PCR amplifications were performed in a GeneAmp PCR System 9700 (Perkin Elmer
Applied BioSystems). Amplification was initiated with a 94oC hot start for 3 minutes.
Amplification was then performed for 28 cycles with denaturation at 94oC for 30
seconds, annealing at 60oC for 1 minute, and extension for 30 seconds at 72oC. PCR
amplifications were performed in a GeneAmp PCR System 9700 (Perkin Elmer Applied
BioSystems). PCR products were separated on 2% ethidium bromide stained gels and
visualized using Eagle Eye (Stratagene). Expected neo amplicon size was 385 bp.
All DNA samples were evaluated for template integrity using PCR amplification of
GAPDH. GAPDH primers were also obtained from Biosource International and diluted
with autoclaved water to 1 µg/µl.

GAPDH primers sequences were: (sense) 5’-

TGAAGGTCGGTGTGAACGGATTTGG-3’ and
(antisense) 5’-ACGACATACTCAGCACCGGCCTCAC-3’. Reaction conditions were as
described above for neo primers.
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RESULTS
PCR Strategy to Detect Targeted C-myb Allele. C-myb null mice were generated by
breeding heterozygous animals. In order to construct appropriate breeding pairs, it was
necessary to genotype parental animals. Genotyping was done by PCR amplification of
genomic DNA acquired from adult tail clippings.

Mating of heterozygous male and

female mice will result in wild-type, heterozygous, and homozygous null embryos in
each pregnancy. In these experiments, embryos from pregnant heterozygous females
were examined at day 13.5, before c-myb null embryos expired in utero. At day 13.5,
there is little phenotypic difference between wild-type, heterozygous, and c-myb null
animals. Therefore, genotypic analysis was also needed to determine which embryos
were c-myb knockout animals. In order to genotype c-myb animals, a PCR strategy
developed by Mucenski et al was utilized. We used one set of primers which were
complimentary to sequences in exon 6 of the c-myb gene. Additionally, these primers
flanked the 1348 kb neomycin cassette inserted to inactivate the c-myb gene (see figure
1).

PCR amplification of genomic DNA from embryos or tail cuttings revealed the

presence of either one or two bands. Wild-type animals had only one 200 kb band
amplified indicating the neomycin gene was not present in exon 6 of the c-myb gene.
Heterozygous animals had 2 amplicons following PCR, a 200 kb band and a 1548 kb
band. This indicated that both the wild-type c-myb gene and the inactivated c-myb gene
were present. C-myb null animals also exhibited only one band, a 1548 kb band.
Absence of the 200 kb band indicated that no native c-myb gene was present in the
DNA, only c-myb with the neo insertion was present. This PCR strategy provided a
method to distinguish c-myb null mice from wild type and heterozygous animals. It also
provided a way to distinguish wild-type from heterozygous animals for breeding
purposes.
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Neomycin resistance gene
1348 bp
Primer 1

Primer 2

If neo insert is not present: 200 bp
If neo insert is present: 1548 bp

Figure 1. PCR Strategy to Detect Targeted C-myb Allele. Primers were designed to
flank an inserted neomycin resistance cassette in the c-myb gene. Differential bands
can be used to distinguish wild-type, heterozygous, and homozygous null animals. Wildtype animals had only one 200 kb band. Heterozygous animals had 2 amplicons
following PCR, a 200 kb band and a 1548 kb band indicating both wild-type c-myb and
inactivated c-myb were present. C-myb null animals also exhibited only one band, a
1548 kb band.
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CFU-GM Progenitor Cells are Present but Drastically Decreased in C-myb
Knockout Mice. In their original description of the c-myb null mouse, Mucenski et al
had reported an 88% decrease in the number of progenitor cells capable of forming GM
colonies in methylcellulose from c-myb null livers as compared to wild type livers. This
experiment was repeated in the current report to ensure that this experimental system
was similar to the one described by Mucenski. Culture of 1 x 105 live fetal liver cells
from wild-type, heterozygous, or homozygous null mice in methylcellulose resulted in a
significant decrease in CFU-GM progenitors obtained from the c-myb null mice as
compared to wild-type or heterozygous animals. As reported by Mucenski, there was
no CFU-GM difference between wild-type and heterozygous animals while there was
greater than an 80% decrease in c-myb null CFU-GM progenitors (Figure 2). This
indicates that, as previously reported, myelopoiesis is severely impaired in mutant cmyb animals.
Often, deletion of a single gene or protein has differential effects on males and
females. As c-myb embryos were harvested, they were genotyped using PCR. In all
experiments, the difference between males and females was examined. No difference
between male and female mice was observed in any experiment conducted. Therefore,
all data presented includes both male and female embryos.
Cellular Composition of C-myb Fetal Livers.

Mucenski et al reported a significant

reduction in the total number of cells found in c-myb null fetal livers as compared to
wild-type fetal livers.

C-myb knockout mice examined in the current report had

approximately 3 x 106 white blood cells per fetal liver while c-myb wild-type mice had
approximately 16 x 106 white blood cells on day 13.5 (Table 1). However, Mucenski et
al did not determine the number of lymphocytes present in the fetal livers of c-myb mice.
Examination of fetal livers at day 13.5 post-coitus indicated that 22% of fetal liver cells in
the wild-type mice were lymphocytes. 2.3% of wild-type fetal liver cells were B220+
while 0.5% were IL-7R+. In contrast, only 0.1% of the c-myb knockout fetal liver cells
were lymphocytes, 0.6% were B220+, and 0.01% were IL-7R positive. In the wild-type
animals, 12% of the cells that fell within the lymphocyte gate were B220+ cells. This
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number was significantly increased in the c-myb null animal; 67% of the lymphocytes
were B220+.

This indicates that c-myb knockout mice not only have a severe

impairment in myelopoiesis, but there is also a marked defect in B lymphopoiesis.
Mutations in C-myb Ablate Clonable, IL-7 Responsive Pro-B Cell Potential.
Although the number of lymphocytes is decreased in c-myb null fetal livers, there were
B220+, IL-7R+ lymphocytes present. We determined whether lymphocytes present in
the c-myb null fetal liver were IL-7 responsive lymphocytes. To accomplish this 96 well
plates were coated with S10 stromal cells that have been shown to support B
lymphocyte development. 100 fetal liver cells were plated per well, and 20 U/ml of
exogenous IL-7 was added to each well. Cells were cultured for 2 days, exogenous IL7 was added again, and cells were cultured for 3 more days. After 5 days of cultures,
individual wells were examined for the presence of expanded B cell progenitor colonies.
Wells with 10 or more expanded cells were scored as positive. As demonstrated in
Figure 3, the numbers of clonable IL-7 responsive cells in the wild-type fetal livers were
not significantly different from the numbers present in the heterozygous animals.
However, the c-myb null fetal livers had almost no cells that were capable of forming IL7 responsive pro-B cell colonies. In addition, the numbers of progenitor cells capable of
forming IL-7 colonies in methylcellulose (CFU-IL-7) were examined. 2.5 x 105 fetal liver
cells were plated in methylcellulose, incubated for 7 days with IL-7, and then examined.
The CFU-IL-7 data paralleled those data obtained in figure 3; no IL-7 responsive
colonies were obtained from c-myb null fetal livers. Finally, we tried to develop a pro-B
cell line from c-myb null fetal livers similar to C1.92 pro-B cells that were described
earlier in this work. Fetal livers were dispersed into single cell suspension and the nonadherent cells were passaged in the presence of the cloned bone marrow stromal cell
line, S10, and exogenously added IL-7. Although several attempts were made, no
lymphocytes from c-myb null fetal livers survived in culture long term.
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Figure 2. CFU-GM Progenitor Cells are Present but Drastically Decreased in Cmyb Knockout Mice.

105 live fetal liver cells from wild-type, heterozygous, or

homozygous null mice were plated in methylcellulose.
enumerated after 7 days in culture.

CFU-GM colonies were

Data are presented as mean and SEM of a

minimum of 3 mice per group.
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FL cells x 10-6

Lymphocytes x 10-5

B220+ cells x 10-5

IL-7R+ cells x 10-3

+/+

16 + 2.7

36 + 5.7

4.4 + 0.7

64 + 12

+/-

12 + 2.6

39 + 8.2

6.7 + 2

38 + 12

-/-

3.1 + 0.5

0.3 + .02

0.2 + .03

0.4 + 0.2

Table 1. Cellular Composition of C-myb Fetal Livers. Fetal livers were harvested
from wild-type, heterozygous, and homozygous null c-myb mice. Cells were dispersed
into single cell suspension and white blood cells were enumerated. Cells were stained
for B220 (CD45R) and IL-7 receptor.

FACS analysis was completed on stained cells.

Data are presented as mean + SEM of a minimum of 3 animals per group.
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# of clonable IL-7 responsiv e cells/ 105 cells/
f etal liv er
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Figure 3.

+/-

-/-

Mutations in C-myb Ablate Clonable, IL-7 Responsive Pro-B Cell

Potential. 100 live fetal liver cells were plated into individual wells of a 96 well plate
coated with stromal cells. IL-7 was added to cultures at day 0 and day 2. Plates were
incubated for 5 days and then the number of IL-7 responsive pro-B cell colonies formed
was determined. Data are presented as mean + SEM of a minimum of 3 animals per
group.
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PCR Strategy to Detect Targeted A-myb Allele. From previous literature it is known
that a-myb null mice do not expire in utero, but males are unable to father pups due to
sterility and mothers are not able to nurse pups due to mammary gland defects.
Therefore, a-myb knockout mice also were generated by breeding heterozygous
animals. As with c-myb animals, it was necessary to genotype parental animals via tail
cuttings to ensure that heterozygous male and female mice were bred. Although the amyb deletion is not an embryonic lethal, the deletion was also examined in embryos at
day 13.5 of gestation in order to compare effects of a-myb deletion with c-myb deletion.
As previously described for c-myb, embryos from pregnant heterozygous females were
examined at day 13.5. At day 13.5, no phenotypic difference existed between wild-type,
heterozygous, or a-myb null animals. Genotypic analysis was necessary to detect amyb null animals. To genotype a-myb animals, a PCR strategy was developed by this
laboratory. As detailed in the methods, two sets of PCR primers were utilized. The first
primer set was complimentary to sequences in exon 4 of the a-myb gene.

These

primers amplified a 200 kb region of the native a-myb gene. However, these primers
also flanked the inserted neo cassette. These primers differed from c-myb primers
because a-myb primers will not produce a detectable amplicon if the neomycin gene is
inserted. This is most likely due to the high A/T content of the primers, resulting in
decreased primer fidelity. To detect the inserted neo cassette, we used another set of
primers specific for the neomycin gene. If the neomycin gene was present, a 385 kb
band was detected.

PCR amplification of genomic DNA from embryos or tail cuttings

revealed either one or two bands.

Wild-type animals had only one 200 kb band

amplified. This indicated that the neomycin gene was not present in exon 4 of the amyb gene. Heterozygous animals had 2 amplicons following PCR with both primer
sets, a 200 kb band and a 385 kb band. These data indicated that both the wild-type amyb gene and the neo cassette were present. A-myb null animals also exhibited only
one band, a 385 kb band. Absence of the 200 kb band indicated that no native a-myb
gene was present in the DNA, only a-myb with the neo insertion was present. Like the
previously described PCR method, this two-step PCR method also provided a method
to distinguish a-myb null mice from wild type and heterozygous animals as well as a
way to distinguish wild-type from heterozygous animals for breeding purposes.
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A.

Neomycin resistance gene
1348 bp
Primer 1

Primer 3

Primer 4

Primer 2

B.
+/+

If neo insert is present: 385 bp band
If neo insert is not present: 200 bp band

+/-

-/-

A-myb
Neo
GAPDH

Figure 4. PCR Strategy to Detect Targeted A-myb Allele. (A) One set of primers
was complimentary to sequences in exon 4 of the a-myb gene on either side of the
inserted neomycin cassette.

The second set of primers was complimentary to

sequences within the neomycin resistance cassette. (B) Differential band sizes can be
used to distinguish wild-type, heterozygous, and homozygous null animals. Wild type
animals have an amplicon using a-myb primers, but no neo amplicon. Heterozygous
animals have a PCR product for both a-myb and neo. Homozygous null animals only
display an amplicon after neo amplification; no a-myb amplicon is detected.
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CFU-GM Progenitor Cells Are Present in A-myb Knockout Mice. To compare the
effects of the a-myb mutation with the drastic effects observed with the c-myb mutation,
a-myb null mice were also examined at day 13.5 of gestation. CFU-GM potential of the
a-myb knockout animal was examined. Livers were harvested from day 13.5 embyos
from pregnant heterozygous a-myb females, dispersed into single cell suspension, and
enumerated. Unlike the c-myb animals, there was no difference in the number of total
cells in wild-type, heterozygous, or homozygous null fetal livers. On average, a-myb
wild-type and heterozygous fetal livers contained 7.42 x 106 ( + 9.4 x 105 ) white blood
cells while a-myb null fetal livers had 6.31 x 106 ( + 1.2 x 106) white blood cells. 105 live
fetal liver cells from each mouse were plated into methylcellulose with exogenous
addition of GM-CSF cytokine. Cells were cultured for 7 days then the numbers of
colonies formed were counted. As shown in Figure 5, no differences were observed in
the number of GM progenitor cells in a-myb wild-type and heterozygous fetal livers
versus a-myb null fetal livers.

In addition, male and female a-myb animals were

independently examined in these experiments. This was done because effects of the amyb deletion are expressed differently in males and females. Although there is a slight
reduction in the number of CFU-GM colonies found in a-myb

-/-

females, the difference

is not statistically significant. These data indicate that, unlike mutations in the c-myb
gene, mutations in the a-myb gene have no effect on GM progenitor cells found in the
day 13.5 fetal liver.
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Figure 5. CFU-GM Progenitor Cells Are Present in A-myb Knockout Mice. 105 live
fetal liver cells from wild-type or homozygous null mice were plated in methylcellulose.
CFU-GM colonies were enumerated after 7 days in culture. Data is presented as an
average of atleast 3 animals +/- SEM.
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A-myb Mutation Does Not Alter Pro-B Cell Frequency. Finally, this report examined
the number of white blood cells present in a-myb null fetal livers that were clonable, IL-7
responsive lymphocytes. As described above, a pro-B cell assay was employed. 96
well plates were coated with S10 stromal cells that can support B lymphocyte
development. 100 fetal liver cells were plated per well, and 20 U/ml of exogenous IL-7
was added to each well. Cells were cultured for 2 days, exogenous IL-7 was added
again, and cells were cultured for 3 more days. After 5 days of cultures, individual wells
were examined for presence of expanded B cell progenitor colonies. Wells with 10 or
more expanded cells were scored as positive.

As demonstrated in Figure 6, the

numbers of clonable IL-7 responsive cells in the wild-type fetal livers were not
significantly different from the numbers present in homozygous null animals.
Additionally, the numbers of progenitor cells capable of forming IL-7 colonies in
methylcellulose (CFU-IL-7) were examined. 2.5 x 105 fetal liver cells were plated in
methylcellulose, incubated for 7 days with IL-7, and then examined. The CFU-IL-7 data
paralleled those data obtained in figure 6; no statistically significant difference in IL-7
responsive colonies was observed between wild-type and homozygous null fetal livers.
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Figure 6. A-myb Mutation Does Not Alter Pro-B Cell Frequency. 100 cells from amyb wild-type or homozygous null fetal livers were plated into individual, stromal cell
coated wells of 96 well plates. After incubation for 5 days with exogenously added IL-7,
wells with clonable IL-7 responsive colonies were counted. Data is presented as the
average of atleast 3 mice + SEM.
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DISCUSSION
Animal models harboring a mutation in one or more genes are valuable tools
used to investigate the role specific genes play in development. Often, mutating a
single gene can have deleterious effects on development. This is the case for several
genes, including the proto-oncogene c-myb. Homozygous inactivation of c-myb results
in embryonic lethality at days 14 to 15 of gestation due to a loss of fetal liver
erythropoiesis.

Other mutations, however, have less dramatic effects.

This

phenomenon is observed in animals harboring homozygous mutations of the a-myb
gene. Inactivation of the a-myb gene results in male sterility and defects in mammary
gland development, but does not prevent embryo formation. The original reports that
describe the myb mutations discuss the most obvious defects associated with animals
harboring the mutations. The objective of this report was to investigate an area not
previously described by literature:
lymphopoiesis.

the effect of a- and c-myb deletions on B

These data indicate that inactivation of the c-myb gene completely

ablates B lymphopoiesis in the murine fetal liver while inactivation of the a-myb gene
does not significantly alter fetal liver B lymphopoiesis.
In order to differentiate between wild-type, heterozygous, and homozygous null
embryos, a genotyping strategy was needed. Mucenski et al had previously developed
a PCR based strategy for genotyping c-myb animals, which was employed in this report.
However, a PCR based strategy had not been developed for genotyping a-myb animals.
We tried to mimic the PCR strategy used by Mucenski et al using one set of primers
complimentary to exon 4 of a-myb that flanked the neomycin cassette. However, due to
the high A/T content of the a-myb gene, we could not design a set of primers to amplify
the entire length of the neomycin cassette plus 200 bases of the a-myb gene.
Therefore, a second set of primers was designed that amplified a region within the neo
cassette. This required two separate PCR reactions, but allowed for detection of the
native a-myb gene, the neo insert, and the a-myb gene containing a neo insert.
C-myb mutant animals expire at approximately day 15 of gestation. Therefore
we analyzed embryos at day 13.5, before the mutation was lethal. In order to compare
effects of the c-myb mutation with the a-myb mutation, a-myb mice were also examined
at day 13.5 of gestation. All experiments described in this report were performed on
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fetal livers from day 13.5 embryos. Fetal livers from day 13.5 c-myb null mice had
significantly reduced numbers of white blood cells when compared to fetal livers of wildtype and heterozygous animals. There was a 10 fold decrease in the number of cells
present in the c-myb null livers as compared to wild-type livers. However, in a-myb
animals, there was no difference in the number of cells in the wild-type fetal liver versus
fetal livers harboring a homozygous a-myb null mutation. These data indicate that while
inactivation of the a-myb gene does not impact proliferation of fetal liver cells,
inactivation of the c-myb gene leads to significant impairments in fetal liver cell
expansion.
CFU-GM potential was evaluated in both a- and c-myb animals.

In animals

deficient for c-myb, there was greater than an 80% reduction in the number of CFU-GM
progenitors as compared to wild-type animals. These data agreed with those results
reported by Mucenski et al (Mucenski, 1991). In a-myb animals, however, the numbers
of CFU-GM progenitors were the same in wild-type and in heterozygous null livers. In
addition, CFU-GM progenitor numbers were evaluated in males and females. This was
done because effects of the a-myb mutation are displayed differently in male and
female animals. In males, a-myb inactivation results in sterility and spermatogenesis
defects. In females, however, sterility does not result from inactive a-myb. A-myb
mutant females can birth offspring but display an inability to nurse pups due to defective
breast development. Although the a-myb mutation results in different phenotypes in
males and females, the effects of the mutation on GM progenitor cell formation is not
gender specific.

Neither males nor females had altered numbers of fetal liver GM

progenitor cells. These data indicate that a-myb and c-myb mutations have differential
effects on GM progenitor formation.

While loss of c-myb severely decreases GM

progenitor potential, loss of a-myb does not alter GM progenitor cell numbers.
In order to evaluate the role a- and c-myb play in B lymphopoiesis, colony
forming units in response to IL-7 were evaluated. CFU-IL-7 progenitor potential was
first evaluated in c-myb deficient animals. Mice harboring a homozygous null mutation
of the c-myb gene had no IL-7 colonies formed above no cytokine controls. Loss of cmyb function resulted in a complete abrogation of IL-7 progenitor cell expansion. To
confirm these results, a pro-B cell assay was utilized. Plating 100 fetal liver cells from c-
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myb homozygous null mice into individual wells of a 96 well plate resulted in no clonable
IL-7 responsive cells. Also, the number of fetal liver cells cultured was increased to 200
cells per well. Still, no clonable IL-7 pro-B cells were obtained from c-myb mutants.
These data correlated well with CFU-IL-7 data; no IL-7 responsive pro-B cells could be
cultured from c-myb null fetal livers. Therefore, while both wild-type and heterozygous
fetal livers contained clonable IL-7 responsive pro-B cells, B lymphopoiesis was absent
in c-myb null animals. In animals with a mutated a-myb gene, the numbers of fetal liver
pro-B cells were no different than those in wild-type litter mates. In addition, there was
no difference in the numbers of IL-7 responsive pro-B cells present in males or in
females. These data suggest that B lymphopoiesis is severely damaged in animals
containing mutated c-myb genes, but is unaltered in animals with a-myb mutations.
Overall, data presented in this report demonstrate that B lymphopoiesis is almost
completely ablated in animals harboring a mutant c-myb gene.

Even at day 13.5,

before the c-myb mutation is lethal, B lymphopoiesis is significantly altered. Taken
together with the previous work presented by Mucenski et al, this suggests that c-myb is
critical for development of both myeloid and lymphoid lineage cells. It is reasonable to
suggest two possibilities for the observed defect in B lymphopoiesis. First, it is possible
that loss of c-myb results in an intrinsic defect in early B cell progenitors that prohibits
them from expanding within the fetal liver compartment. Secondly, it is possible that the
microenvironment of the fetal liver is altered and is no longer permissive for lymphocyte
expansion. Most likely, the defect in B lymphopoiesis is a combination of an altered
microenvironment as well as progenitor cells with impaired proliferative capacity. In
contrast, inactivation of the a-myb gene does not significantly impact B lymphopoiesis at
all. Although a-myb is expressed in different cell types than c-myb, the two display
highly homologous DNA binding regions.

Both a-myb and c-myb bind the same

consensus DNA site on target DNA. How the two proteins exhibit differential effects is
not completely understood, especially given their similar DNA binding preferences. This
report indicates that, although they are highly homologous proteins, a-myb and c-myb
play largely different roles in the development of B lymphopoiesis. C-myb is critical for
normal development of B lymphopoiesis since mice with a homozygous deletion of cmyb have a complete loss of B cell development in the fetal live. However, a-myb is not
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essential to B cell development as evidenced by unaltered B cell development in mice
with a homozygous null mutation of a-myb. Taken together these data suggest that,
although a- and c-myb are closely related proteins, they do not play redundant roles in
the development of B lymphocytes.
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Chapter 5

General Conclusions
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The overall goal of this study was to investigate the role of the proto-oncogene cmyb in B lymphopoiesis. We undertook this study because the current literature has
focused on the role of c-myb in proliferation and differentiation of erythroid, myeloid, and
T lymphoid cells, but far less is known about the role of myb in B lymphoid
development. Our studies led to several novel observations: 1). C-myb is expressed at
high levels in pro-B cells, 2). The half-life of c-myb mRNA is long lived in pro-B cells
while the protein half-life is less than 1 hour, 3). Stromal cells regulate c-myb expression
in pro-B cells, 4). C-myb is an intracellular regulator of proliferation in pro-B cells, 5). Cmyb is an intracellular regulator of differentiation in early B lymphocytes, 6). C-myb does
not regulate survival in pro-B cells, and 7). C-myb knockout animals exhibit a complete
failure of fetal liver lymphopoiesis while animals deficient for a-myb do not exhibit any
alterations in B cell development.
The first goal of this dissertation was to determine the normal expression patterns of
c-myb in developing B lymphocytes. Previous literature reported that late stage pro-B
cells (those with D-J rearrangement of the heavy chain gene) do not express c-myb.
We utilized a pro B cell line which does not have Ig gene rearrangements to investigate
c-myb in B lymphopoiesis. C1.92 was cloned from fetal liver. This cell line retains
dependence on stromal cells and IL-7, and retains Ig heavy chain genes in germline
configuration. This cell line is characterized as an early B cell progenitor line because
the D-J region of the heavy chin gene remains germline and the cells continue to
express CD43 along with CD45R (B220). C1.92 cells cultured with stromal cell support
proliferate continuously in culture and do not differentiate. In addition, expression of cmyb remains high throughout their life cycle. Since the C1.92 cell line is an early pro-B
cell that still retains c-myb expression, it is a useful model to examine c-myb expression
and regulation. Our data demonstrate that C1.92 pro-B cells express both mRNA and
protein for c-myb.
C1.92 cells are similar in developmental status to the myeloid cell line HL-60. HL-60
cells are pro-myelocytes that continually proliferate in culture but do not differentiate.
HL-60 cells are also characterized by high expression levels of c-myb. The C1.92 cell
line is a model system similar to HL-60 cells, but lymphoid in nature. This provides a
model of lymphocyte development which can be compared to c-myb data reported for
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myeloid cells.

In order to complete assays at biologically relevant times, it was

necessary to determine the degradation kinetics of c-myb in lymphoid cells. The halflife of c-myb mRNA and protein in myeloid cells is approximately one hour (E Westin,
personal communication).

However, when the half-life of c-myb in pro-B cells was

evaluated we determined the half-life of c-myb mRNA to be long lived. Inhibition of
mRNA transcription revealed the c-myb mRNA half-life to be approximately 11 hours.
Conversely, the half-life of c-myb protein was short; inhibition of mRNA translation
revealed the half-life of c-myb protein to be less than 1 hour. Therefore, while the halflife of c-myb protein is similar in lymphoid and myeloid cells, the half-life of c-myb
protein is much longer in pro-B cells than in myeloid cells. These data establish the
degradation kinetics of c-myb mRNA and protein in early pro B cells and demonstrate
that c-myb is expressed continuously at high levels in an early pro-B cell model.
The second goal of this dissertation was to determine whether stromal cells
regulated to expression of c-myb in pro-B cells. Developing B cells within the bone
marrow are dependent upon the bone marrow microenvironment for normal
development.

In particular, bone marrow stromal cells are known to regulate the

survival, proliferation, and differentiation of developing B lymphocytes. Much of this
regulation is accomplished through molecular changes in specific gene expression.
One particular gene, c-myb, is known to be regulated during development in myeloid
cells. Since stromal cells are important in regulating several other genes important in B
cell development, we wanted to investigate whether stromal cells also regulated c-myb
expression in C1.92 cells. The data presented here demonstrate that stromal cells are
also responsible for regulating c-myb in C1.92 cells. Culturing C1.92 cells in media
alone, without the support of stromal cells, resulted in a decrease in both c-myb mRNA
and protein within 8 hours. A decrease in c-myb mRNA was observed within 6 hours,
indicating that loss of stromal cell support resulted in an active degradation of c-myb
mRNA. However, it is known that stromal cells can regulate gene expression both by
adhesion contacts and by producing numerous cytokines.
Our next aim was to determine whether stromal cells regulated c-myb expression
through cytokine production or via adhesion contacts. Using a transwell culture system,
it was determined that stromal cell adhesion contacts are largely responsible for
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maintaining c-myb expression. Although loss of stromal cell adhesion contacts did not
completely ablate c-myb expression, it was significantly decreased. This indicates that
although both stromal cell cytokine support and stromal cell adhesion molecules are
involved in c-myb expression, stromal cell adhesion contacts are mainly responsible for
the maintenance of c-myb expression in early B lymphocytes.
There are three hallmarks of the life of developing blood cells: the ability to survive,
proliferate, and differentiate. Mechanisms that regulate these three fundamental events
are not well understood. Our working hypothesis was that c-myb regulated proliferation
and differentiation of developing B linage cells in the bone marrow. Therefore, the next
goal of this work was to determine if c-myb was an intracellular regulator of proliferation
in developing B lymphocytes.

It is well documented that c-myb regulates the

proliferation and expansion of myeloid, erythroid, T, and transformed B cells. This study
investigated if proliferation in normal progenitor B cells was regulated by c-myb.
Although culturing pro-B cells without stromal cells effectively downregulated c-myb, this
is not the best method to use to investigate regulation of c-myb in pro-B cells because
this results in initiation of apoptosis. In order to downregulate c-myb without initiating
cell death in pro-B cells, treatment of cells with DMSO or antisense oligonucleotides
was utilized.

Treatment of pro-B cells with DMSO or antisense oligonucleotides

resulted in decreased c-myb protein as detected by western blot analysis. Following cmyb downregulation by either of these treatments, pro-B cells failed to expand in
culture. When cells were enumerated after c-myb downregulation, cultures treated with
antisense oligonucleotides or DMSO had significantly fewer cells. When pro-B cells
with downregulated c-myb levels were put into a proliferation assay, there was a
significant decrease in their ability to respond to the proliferative cytokine interleukin-7.
Analysis of their cell cycle profile using propidium iodide revealed that pro-B cells with
decreased c-myb levels had an increased proportion of cells in the G0/G1 phase of the
cell cycle with fewer numbers of cells in the S and G2/M phases of the cell cycle. These
data indicated that downregulation of c-myb resulted in an inhibition of proliferation by
blocking cells in the G0/G1 phase of the cell cycle. This suggested that c-myb is an
intracellular regulator of proliferation in pro-B cells.
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Since pro-B cells exhibited alterations in proliferation and cell cycle profiles, we were
interested in determining whether cells were exiting the cell cycle and beginning to
differentiate.

Our next goal was to determine whether c-myb was an intracellular

regulator of differentiation in early B lymphocytes. One way to follow B cell maturation
is to follow changes in cell surface markers. C1.92 cells express low levels of B220,
high levels of CD43, low levels of CD24 (HSA), and low levels of flt-3. If phenotypic
maturation is occurring, B220, CD24, and flt-3 levels should increase while CD43
expression should decrease. However, after downregulation of c-myb, no alterations in
these cell surface molecules were observed. Although phenotypic maturation was not
observed, we investigated genotypic alterations.

As pro-B cells mature into

immunoglobulin bearing B cells, rearrangement of the immunoglobulin genes occurs.
Genetic reorgantization and juxtaposition of a single variable (V), diversity (D), and
joining (J) region from the Ig heavy chain gene is required for expression of
immunoglobulin. Tracking rearrangement of the heavy chain genes is the most reliable
way to follow B cell maturation. Utilizing PCR, we determined that downregulation of cmyb by DMSO treatment resulted in rearrangement of Ig heavy chain genes.

In

addition, surface immunoglobulin was detected on C1.92 cells with downregulated cmyb expression.

These data indicated that downregulation of c-myb resulted in

genotypic maturation of pro-B cells to Ig expression. However, phenotypic maturation
was uncoupled from genotypic maturation because c-myb downregulation did not alter
the cell surface phenotype of pro B cells.

These data suggest that c-myb is an

intracellular regulator of differentiation in pro-B cells, but that add additional signals are
required for completion of phenotypic (and maybe functional) maturation.
The next objective of this report was to determine whether c-myb was an
intracellular regulator of survival in developing B lymphocytes. It is known that pro-B
cells require stromal cell contact for their continued survival. And, we have previously
shown that stromal cells regulate c-myb expression in pro-B cells.

We wanted to

determine if the survival signals provided by stromal cells were c-myb dependent.
When c-myb was downregulated by DMSO or antisense treatment, C1.92 cells
exhibited no decrease in cell viability. In addition, staining with propidium iodide and
examination of DNA did not reveal the onset of apoptosis. This indicates that, although
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stromal cells regulate c-myb expression in pro-B cells, c-myb does not regulate the
survival of developing B lymphocytes.
Finally, we wanted to utilize the currently available myb knockout models and
determine whether lymphopoiesis occurred in these mutant animals. C-myb knockout
mice die at day 15 of embryogenesis due to loss of erythropoiesis in the fetal liver.
However, B lymphopoiesis has not been described in these animals. Examinations of
the fetal livers of day 13.5 mutant c-myb animals revealed that no lymphopoiesis was
occurring in these animals.

No CFU-IL-7 progenitors were present in c-myb null

animals and no clonable IL-7 responsive pro-B cells were present. These data suggest
that the loss of c-myb during embryogenesis completely ablated B lymphopoiesis in the
fetal liver. Conversely, when the fetal livers of day 13.5 a-myb null fetal livers were
examined, B lymphopoiesis was completely intact.

This indicates that c-myb is

necessary for B lymphopoiesis while a-myb is dispensable. Although a-myb and c-myb
exhibit high homology and share affinity for the same consensus DNA binding site, they
are not redundant in their role in B lymphopoiesis.
Taken together, these data provide a working model for the role of c-myb in B cell
development. Pro-B cells require stromal cell interactions for maturation within the bone
marrow microenvironment. Stromal cell contacts are responsible for maintaining high
levels of c-myb in early pro-B cells and this expression is directly related to observed
high proliferative capacity of these cells. Pro-B cells are the primary expanding cell
compartment of the B lineage, therefore a high proliferative capacity is necessary to
produce enough progenitor cells to populate the entire animal. However, as pro-B cells
loose their dependence on stromal cells, they exhibit decreased proliferative potential.
It is at this time that c-myb levels decrease. As c-myb levels abate, proliferation ceases
and genotypic maturation occurs. These changes allow pro-B cells to differentiate into
surface immunoglobulin positive B cells. These data clearly demonstrate that cellular
interactions between stromal cells and pro-B cells regulate molecular events within
developing B cells. In turn, these changes in molecular molecules, particularly in c-myb
expression, determine the fate of immature B linage cells.
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RNA Primers
Primer
Name

Sense Primer Sequence (5’- 3’)

Antisense Primer Sequence (5’- 3’)

GAGCTTGTCCAGAAATATGGTCCGAAG

GGCTGCCGCAGCCGGCTGAGGGAC

ACCCTGAGAAGGAAAAGCGAA

GTTTTCACAGTCTGGTCTCGA

AAGCGAATAAAGGAGCTGGAGT

TGGTGGACGATCATGCACCT

ATGGGCGCCCCACTCAACT

TATCAGTCCGTCCGGGCA

B-myb

ATGTCTCGGCGGACGCGCTGCGAG

CTGTTCCTTGTCCTCCAGCTCCAGG

B-myb

ACGAGCCTGCCCTACAAGTG

TGGCGTGTGGGGAGTGTTGT

Actin

CACAGCTTCTTTGCAGCTCC

GGATCTTCATGAGGTAGTCTGTC

IGF-1

GACCCTTTGCGGGGCTGAGCTGGT

CTTCTGAGTCTTGGGCATGTCAGT

IL-6

AACAGACCTGTCTATACC

GTACTCCAGAAGACCAGA

IL-7

GCCTGTCACATCATCTGAGTGCC

CAGGAGGCATCCAGGAACTTCTG

Primer
Name

Sense Primer Sequence (5’- 3’)

Antisense Primer Sequence (5’- 3’)

GAPDH

TGAAGGTCGGTGTGAACGGATTTGG

ACGACATACTCAGCACCGGCCTCAC

DFL16.1

GCCTGGGGAGTCACTCAGCAGC

GTGTGGAAAGCTGTGTATCCCC

JH1

CCCGGACAGAGCAGGCAGGTGG

GGTCCCTGCGCCCCAGACA

Syr

AAGCGCCCCATGAATGCATT

TCCCAGCTGCTTGCTGATCT

Neo

GATGGATTGCACGCAGGTTCTCCGG

ATGGGCAGGTAGCCGGATCAAGCGT

C-myb

GCAAGGTGGAACAGGAAGGCTACC

GTGCTTCGGCGATGTGGTAATAGG

A-myb

GTATACTTAAATTTGGGCTAATTT

TAAATTTTTTCAAAAGAATATGAA

C-myb
exon 4
C-myb
exon 8/10
C-myb
exon 8/9
C-myb
start site

DNA primers
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Antibodies:

Antibody

GAPDH
C-myb
CD45R
CD45R
RAG-2
RAG-1
Ly-51
(BP-1)
CD24
(HSA)
CD24
(HSA)
CD43
CD43
CD135
(Flt-3)

Isotype
Monoclonal
mouse anti
rabbit
Mouse
monoclonal
Rat anti
mouse
Rat anti
mouse
Mouse
monoclonal
Mouse antimouse
Rat antimouse
Rat antimouse
Rat antimouse
rat antimouse
rat antimouse
Rat antimouse

Tag

Clone

Supplier

IgG2b

Purified

6C5

IgG2aκ

Purified

1-1

Research
Diagnostics
Inc.
Upstate
Biotechnology

IgG2aκ

FITC

RA3-6B2

Pharmingen

IgG2aκ

R-PE

RA3-6B2

Pharmingen

IgG2b

Purified

G110-461

Pharmingen

IgG2b

Purified

G109-256

Pharmingen

IgG2aκ

FITC

6C3

Pharmingen

IgG2cκ

Purified

30-F1

Pharmingen

IgG2bκ

FITC

M1/69

Pharmingen

IgG2aκ

FITC

S7

Pharmingen

IgG2aκ

PE

S7

Pharmingen

IgG2aκ

PE

A2F10.1

Pharmingen

IL-7R

Purified
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Isotype Antibodies:

Antibody

Isotype

Tag

Clone

Supplier

Mouse IgG1 Isotype

IgG1,κ

Purified

15H6

Southern Biotechnology

Mouse IgG2a Isotype

IgG2a,κ

Purified

HOPC-1

Southern Biotechnology

rat IgG2a isotype

IgG2a,κ

R-PE

R35-95

Pharmingen

Rat IgG2b isotype

IgG2b,κ

Purified

A95-1

Pharmingen

Rat IgM

IgM,κ

Purified

R4-22

Pharmingen

Mouse IgG2b isotype
(anti-dansyl)

IgG2b,κ

Purified

27-35

Pharmingen

Goat anti-rat IgM +IgG
Goat anti mouse Ig

IgM +IgG
(H+L chain
specific)
Ig (H+L)
Chain
specific

Purified

Southern Biotechnology

Purified

Southern Biotechnology
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